var title_f2_0_2048="Osteitis in congenital syphilis";
var content_f2_0_2048=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Congenital syphilis: Osteitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the extensive destruction, with metaphyseal (arrows) and diaphyseal radiolucencies throughout the humerus, radius, and ulna. Observe the exuberant periosteal overgrowth, with expansile deformity of the bones of the upper extremity. Syphilitic granulation tissue may extend from the metaphysis to the diaphysis, creating an extension of the infectious focus. Reactive sclerosis often surrounds the osteolytic lesions, with associated periostitis of the long tubular bones.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yochum TR, Rowe LJ. Yochum And Rowe's Essentials of Skeletal Radiology, 3rd ed. Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_0_2048=[""].join("\n");
var outline_f2_0_2048=null;
var title_f2_0_2049="Lynch syndrome cancer risk";
var content_f2_0_2049=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Lynch syndrome cancer risk",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 432px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lifetime risk for colon, endometrial, and ovarian cancer in individuals compared with the general population.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      Koornstra JJ, Mourits MJ, Sijmons RH, et al. Lancet Oncol 2009; 10:400.",
"      <br>",
"       Barrow E, Robinson L, Alduaij W, et al. Clin Genet 2009; 75:141.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_0_2049=[""].join("\n");
var outline_f2_0_2049=null;
var title_f2_0_2050="CT of preinvasive lesion - AAH or AIS";
var content_f2_0_2050=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F60122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F60122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT of preinvasive lesion - AAH or AIS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT of preinvasive lesion (AAH or AIS). Axial 2-mm image through the left upper lobe shows a 5-mm pure ground-glass nodule (GGN), which has remained stable for 8 years (arrow). AAH and AIS can be single or multiple.",
"    <div class=\"footnotes\">",
"     AHH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011; 6:244. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_0_2050=[""].join("\n");
var outline_f2_0_2050=null;
var title_f2_0_2051="Knee osteochondrom x ray";
var content_f2_0_2051=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Synovial osteochondromatosis of the knee",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 406px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGWAggDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6ku7mCztZrq7migtoUaSWWVwqRoBksxPAAAJJNc1/wsbwR/0OXhv/AMGkH/xVHxY/5JZ4y/7A15/6IevzYByKAP0o/wCFi+Cf+hx8N/8Ag0g/+KoHxF8Ek4HjHw2T/wBhSD/4qvzXzjpT4XxMp6UAfpXH478IS/6vxVoD/wC7qMJ/9mqX/hM/C/X/AISTRf8AwOi/+Kr8+NHdSwwSr9ueDXW2sn7keYpDDqP60AfbY8Y+GT08RaMf+36L/wCKpw8XeGyePEGkH6Xsf/xVfGsYUbeByMipln2jn8aAPsX/AISzw5/0H9I/8DI//iquW2saZdRh7bUbOZD0aOdWB/EGvjORP3G5WB+h5FevfC64L6Fb+ZkkZUfnQB7q95aohZ7mFV9S4AqA6xpo66jZj/tuv+Ncjfbm06XABA5NcXdYOWIGBz1oA9iXV9NY4XULMn2nX/GpkvrSQgR3UDE/3ZAa8SiZ/MGDwT6102lSnzU3YwDgY7UAeltPEv3pYx9WFU5db0qKQxy6nYpIOqtcID+Waz70ZgyQORmvFvGRWLxE5ORuQH9TQB7wuuaSxwuqWBPtcJ/jTxrGmEZGo2ZH/Xdf8a+erV0wDnr/ACrQ37Yzjp04oA91GsaYemo2Z/7br/jS/wBrabn/AJCFn/3+X/GvBoZmXIG7Oemas2kzndywIBNAHt7axpi/e1GzH1nX/GmHXdJHXVLAf9vCf414YblnYruPJ/Ks2/n8m4wJM4XkDmgD6D/4SHRQcHV9Oz/18p/jUcnibQYwDJrelpnpuu4x/WvmG71JgWGxjk9awLy4leQKrkr/AHSaAPro+LPDg66/pH/gZH/8VTW8X+GkGW8Q6Oo9TexD/wBmr4zuXRnwwZX9zxWddSTKjbTx9aAPtk+NfCoGT4m0QfW/i/8AiqZ/wnnhD/oatA/8GMP/AMVXwhezP5Z3OR9KzllKcg5+tAH3+3jzwgv3vFWgD66jD/8AFVG3xD8FL97xh4cH11OD/wCKr4AnBuFA3dOlc7qLZnIXoOKAP0f/AOFjeCP+hx8N/wDg0g/+Ko/4WN4I/wChx8N/+DSD/wCKr82kyKa2aAP0x0zxt4V1W+istM8TaHe3kpIjgt7+KSR8DJwqsSeAT+FTa14r8O6FdLba3r2k6dcugkWK7vI4XZCSAwDEHGQRn2NfCv7NI/4vh4X/AOuk3/oiSu2/bQ/5Kjpf/YGi/wDR89AH1L/wsXwT/wBDj4c/8GcH/wAVR/wsXwT/ANDj4c/8GcH/AMVX5u0ZoA/SL/hYvgn/AKHHw5/4M4P/AIqj/hYvgn/ocfDn/gzg/wDiq/N3NGaAP0i/4WL4J/6HHw5/4M4P/iqP+Fi+Cf8AocfDn/gzg/8Aiq/N2igD9Iv+Fi+Cf+hx8N/+DSD/AOKo/wCFi+Cf+hx8N/8Ag0g/+Kr83KDQB+kf/CxfBH/Q4+G//BpB/wDFUn/CxvBH/Q4+G/8AwaQf/FV+bZprHmgD9Jx8RfBJOB4x8Nk+n9qQf/FVKPHvg8jjxXoH/gxh/wDiq/N2wi8yQMexrpouRleg7UAffy+OfCbfd8UaEfpqEX/xVSDxn4XIJHiTRSB3+3Rf/FV8GWkm0ita2f5sjlMcigD7fXxf4ab7viHRz9L2L/4qlbxd4bX73iDRx9b2P/4qvi+0k/eYBynvWoqeYmXyBzigD68Xxb4cb7viDSDn0vY//iqkHifQCu4a5pZHr9rj/wAa+L5d0bgoxVz2HQ1p2d67J5bcDoeMZoA+u28VeHlIDa9pIJ6ZvI/8aX/hKfD5Uka7pWB1P2yP/GvlCN/NQBsOoPftSSSJEwyGXd3U8UAfWI8T6AV3DXNL2+v2uPH86t2Gq6fqEZewv7S6QHG6GZXH5g18k6VYXOt6rBYWBP7w8kfwr3Jr6O0y1tfDmjwafAoRwm0sBz7k+9AHWte2qjLXMAHvIBTf7Qs/+fu3/wC/i/41wNw7ByCcq3THao1wxKjt+tAHoYvbQ9LqA/SQU9rmBU3NNEF9S4xXI6Tal2G/hB8zE1i+L9VHmFIW2lR09qAO9m1vSoRmbU7GMer3CD+tRjxForY26xpxB6Yuk/xr5t1fVTqd4IQwQx9uxNMgkKNscYY9/SgD6XGvaO33dW08/S5T/Gnf23pWM/2nY49ftCf4187wzkAADp1961oHWZMDHPbNAH0BHIksaSROrxuAyspyGB6EGiqXh8Y0HTQO1tF/6AKKAMT4sf8AJLPGX/YGvP8A0Q9fmsOtfpT8WP8AklnjL/sC3v8A6IevzWFACk9qF4YYpDQv3hQB0OlyqSAwANdZp1w3lKrfvFHfPIridNkBYA8GuosuOh69qAOpgc+SPl3L6nqBSGQlWUt079KzraRcbWJU+/Sp1JHBwRQBcE5VNhH0avWvhJMz6Ow5O2Q4ryFmBQA8g/pXp/wgkItLiIHpID+lAHsG4/YJ+o+XBribpiASDz6V2sB3WUwI/h+prjLlQytk8jqD3oAro+GB/P2rp9KOChOMY61yjIMDIO71rpNK4VV3cAcGgDupT5liGzzjpXivxGYxa3bOQMFSMGvZYW3aYD1wK8e+KShdQszyDuIoAzLVwQNwBwO3arAdTGw5HPrWXbFyow4/z2qUiTyiCMHPrQBcDLn75FWrOUxySHdxtNY+50QHaSc+lWreVdsjOG5GAB3oAcXKuTuPzDrmsy9dkncBhlefrVm7kYEFc8HNZt3KZLqRyBk9hQBl30g8pssMmuclkAuQQSdo7mtrVMeWT0zn8K5Z2PmuSf0oAtTTo74YDGOorPujuU7DSJlpGI/lUVy+cjvQBlXxZeMfjVBnXBUn9Ks3ZctgH86gYIOWGTQA3PloTnAHTIrnb7H2lyDnJrdvXIgBBPP6Vz04Ib5utADOnel603NKTxQB6b+zUf8Ai+Hhf/rpN/6Ikrtv20P+SpaX/wBgaL/0fPXEfs0/8lw8L/8AXSb/ANESV2/7aH/JUdL/AOwNF/6PnoA8CooooAKKKKACiiigApDS9qaTQAhNMPpSk0+2TzJgPxoA1LGPbF0961bUsrA5AP8AOqEPAx0FaUAwf0oA04VVskfK1WIJdswU8diKrwgbduSD61NGu/h1Oc9fSgDQido5MMDtBzkVtW9xkr2yOnrWSAFAw3GB1q5byRuuzeAw746UAWblBIxPf+VLBIEUhecd6qSTsi7UIYf3j3q5ZiNcGQAH+6KALduzgYUHax69qSeTy1Jl5boF9aRmeQHYRtHbNdX8LfDB8SeIVknj/wCJfancxP8AE3YUAeh/B7wz/YumNrV/Hi6nAIBH3V7Cuj1a6F1O8ytlj1UVralcRxweQgCqvygA9vWubfb5pKAn+7zQA0SsPlbkn9Ks2iGeRVAOfaoWjDMpQ8jrXQaJbLFC92+BtztBoAl1S4Gn6aYkI81uWx1rxPxrryq7QRHM7E7ueldT8RfEn2O1ldSVkPyqTyM1455819cNNON8p7e3tQBo2KmZQT9/PDjtWtta3QGXBJ/HNUbTYqKuSv8AtVYadwBHIAwAx9aALlm4cjBII9elW3uMHKnkehrGTKHKllH+1V6wkRjk44oA+kvDBLeGtJYnJNpCf/HBRR4XwfDWkkdPskP/AKAKKAMj4sf8ks8Zf9ga8/8ARD1+aw96/Sn4sf8AJLPGX/YFvf8A0Q9fmrQA4j0pBwaMmjvQBetDh810+ly5UA84rmLUBiOea3dOJU4oA6SFt4G0jI7Gld9pwRiqsPI3DrVjzcgLIMj1HWgCzvIAIPHua9H+Elxi7uozkA4NeZum5VMTZHpXafC2YxeInjyV3JyKAPoawl/cPg/wnqK5G9cCQjePfiun0pwYWHX5fwrkNVeMXEikHJb8KAK8jMVxnjGQa6HSDwob7x965B1wcq3ABAroNJuW8uJm5YD6UAejWLbrF09s5ry/4sRZtoJmH3ZcZ9K9H0lJVt1kYZhlyAQc4rhvipCG0GQn+Bg360AecxyGJl2sTkVpRzMIsuOT2rDikDGP5gMdea2DcK6hFIPrmgCVpl24zg/Wn2kysX3E4xgcVVk24L7AcdgKe8nk26FQUc9TjrQBFeXJEvzN8o9qxhcvJI7ZBU1aurmVo5DkHPXjpWKsoVJA2d2aAG3k5dWDFcrXPuxO5iBjNa8wUktjjrg1n7Q0BJHGe1AGcjk7gOlV7gnBCgZ9c1eWNypO0KvvVW7CqAM/lQBz1xkSn5uc0hxg55pbyVFlbHP0qpJMT06UARai+639Bmseb5uav3j7oyCeaokfLQBAKD1oYYNAODQB6b+zT/yXDwv/ANdZv/REldt+2j/yVLS/+wNF/wCj564n9mn/AJLh4X/66Tf+iJK7b9tE4+KWl/8AYGi/9Hz0AeB0CkNKKACg0UUAFFGfSkzQAmaRjS9qYTmgBGq7pycMxqj1Natsu1APagC5F27VoWwIwe1Z8fOPrWjCQRxQBcBGR2NaFpOMbXHPY1nxrwSamjUquTQBdnkKkBDmp4P3i5zhj2qhEN5+bgg9R3q4owODzQBahZo5FPp27VoREON5XBJ5xWbAWUDcMirnnmMbtoAoAv2tvPf3dvZWab55mCLj+Zr6a8LaLB4U8Nw2kWPPK5d8cknqTXnvwN8LbIJPEWopgsMQKR0X1/Gu81e+Msp2Eg+lAFO+vWMpBOSe5qsk2Cxxz0GKgkkLSEhCT+lSRRkSIACG6YFAG3o9n586n1XP4Vc8VX8djZlY+EAycelWodum6YZHGJWX8hXkfxH1/c/2SCXLv972FAHE+JdWbW9Tdcn7OjHaCOp9apW1o0cvyEsg5BBpkMLRygMep6Gt22hBiYMoWQcgj+KgCBclOGDA9ef5imlnQHcuU7nr+NW9gLYmUbSOoPNZl45gkb7PIJE7+31FAF6a7ieLaTg4qFCbdQSwHrismGdZ3bd8pHU+lWopUum2E428b+uaAPrLwg2/wnojf3rGA/8AkNaKb4NG3whoYHGLGAf+Q1ooAzfix/ySzxl/2Brz/wBEPX5q1+lXxY/5JZ4y/wCwNef+iHr81aACiiloAngYqVIroLF94DDqOornYula9jIUbjpQB01s2QCv5VYPXPas63c5ypq6r5HNAE68bSODnrXW/D+5CeKbcSjhlIyK5Ff4SMGtrwnN5XiWxbpl9tAH01pBBGFJAI6GuN1kOLmTgHBrq9Dcnb9K5PWpjFfOFBxk5NAGVJMDyAQFre8MQzX1yLe1AZlQv1/GsJpYzEu4DLDqBXXfDeNjqtylvtWaS3ZUycckUAdl4RaT+yb2OUEICNpPPzelcx8RYRL4dvySciMt+VXdK1G+02RrFziMsQ6OOh9qn8WWv2nSrhBgb4z39qAPALSWJpEBJIAya1YruMEhFJz7Vj6fbnJDk5HBresY0ZSPlzQBVe/3SKoiPXHSrd5esxwsZA4GT04psduxumBwFTnIp1yElXZwMdeMUAZ86B1+9gvnjris2SGKMk53epq5fxAIxWQjbWTLII1O4luc8c0AMu5B5T7R2xVHzYba2Xe25uu0VBqd8TblVAArKaQmMZ5oAtXd8So8peD61j3czN945qxNJleBWXcP1oAzZ5MyN9ahaQCknY7uOlV2brQA2Z9x2jpUTHoBS/xc9aQ9aAIJPvmm06T75ptAHp37NP8AyXDwv/10m/8AREldr+2l/wAlT0v/ALA0X/o+euK/Zp/5Lh4X/wCuk3/oiSu0/bS/5KnpX/YGi/8AR89AHgdA4NFFAC0p6Ug6GkoAKKKQmgBCaaTxSk03qaAJrVN0gPYVprwMmq9rHtUZHNa+h2Eep6vbWc9ytrDK2GlboooA2PClm0McmuXMPmafalkIwDlsADg+7Cs+35YccVreJbuG3uRo+jzSHTrVdjEHHmt1Zjjrz/KqFqmMcUAW4xk4xU4XOFFRoMMAKvwR4GTQAJEAoqaMAkbxj0NPxxnjApuc0APB25GSR6iuh8B+HbjxT4kitF3fZYyHmYdl9PxrmcvuSKFS8kh2qg7k19L/AA28Op4P8Kq8wH9oXI3SHvk9h9KAOjvrhNPtEsrUBYYlC4UVzk1y05YgYUHmn6hdF1PBGTzz1rOdvLQgZGR096AJ4ZDv4I4P610Xh21M90ZplJRPmPFc9YoSY0Ubi3412t40ekaOqhsMVyxoA53x5rkdnaTylvkUHvnn0rwQ3Uuo3b3FweXJPHatLxxr0mr6q8cUn+jxNjj+M1hwBgy/yNAGvZD96RIxbHTNalsF5Dqwjz39aydyqQW3Jjr/APqq0l8hjAG3P0xkUAXr9UWBmi6471y4uAu4gEHoas6lfHZiMYX2NZbSeZ9/v7UAaMcSTxZVBlueuN1OsYn3nAYIP4R1FSWCwkqVl49MdK0Jto28sMn7y4oA+o/B3/Io6J1/48YOv/XNaKPBwx4R0MA5AsYOfX92tFAGZ8WP+SWeMv8AsDXn/oh6/NWv0q+LH/JLPGX/AGBrz/0Q9fmrQAUUUUASw1pWbZ21mRdav2hHH1oA3bZyBV5ZDgVnW39aupgNQBajkwn1NaujXHlazYOf4ZV/nWTGAVH1qzbPsu4GH8Min9aAPqrw5IJI0KnGV7iuS8Th0v5Wx045ro/CrBo4O4xXP+KUY30ndSx4FAHOtMzbCoC88iren3c9vc+bbyFJVI2kHpVV22uoA3DvTkCiYqS2Q2RzQB6bPrlvqNhbzSwkampxKwHyuPU+9a2oTrcacrBRynNcFYgrKU3cbePrXa2+JNLVeu0YoA+flmii1O7hZWUJKw4PvWnY3VqFcFjz6is3xVCbXxVfqANpfP51FZKNx3sMnjrQBv8A2y1jAWFWZ2OWJ4qnqF3mViwXA7A4NVbyVfNXYAm3qPaq1zcI+cAD8OTQBXv7jzFYgle1ZMsz7CcgirV3INpxnkVlTElCAeKAKl9IDF7+1U5GbauKLnlAM1HlscEigBJCcHisq7JxxWrJnuay73jd6UAZMvLc1EEPJqaXO6mGgCFsA8c0w9akbqcdKjagCB+WNNpT1pKAPTv2af8AkuHhf/rpN/6IkrtP20v+Sp6V/wBgaL/0fPXF/s0/8lw8L/8AXSb/ANESV2n7af8AyVPSv+wNF/6PnoA8DopKM0ALQaKKACmtSk000AIxqS2Tc+T0FRdTWjax7VHrQBYjGBUpXovehMDk1PbRmR9xHAoAsWsO1RxWlGNgyaihARKu20W4736elAEttGSckdavJygxUKenGO1TxEcgCgB+MJg85qCRwiEk4xUrsFUsxAHvUej6fceINbtdNs1JeZ8Ej+Fe5NAHovwK8LnWNZOtX8f+hWpxDu6M3c/hXr+v6mJZmCnbEhwoFJa2lt4Z0O20qyGDHGFOP1JrmNRu/Mm2g5APPvQBYSZ5XbeSQD1pHYTXKIGJA61Ve5EMPA56fjWloFk08gIBZm6UAdP4Tsh9o+0OAY0GefWuJ+L3iVoo20+yfNzNkcHkDvXe+IdUg8OaBJMzKuxT+Jr5pm1KbVdbm1GUHLbioPQCgCJF8plDrkL97PrVyGElTLA2R/cPWqw4VmJyTzTElbHynABoAutc7z+8TbTpNrfKgOfakFxHJGEmUB+xxUMjGNv3ZJWgCtewMJUHUHqKjiUi4z0HSlnn3T4GSFHQ9aYX2g9RmgDSRcyLtxx1PrWvDMCF3Krgce9YVpM0SZyGB6VZZ9yLgMpzQB9c+EMf8InouOn2KDH/AH7WimeCufBug85/0CD/ANFrRQBnfFf/AJJb4x/7A15/6IevzWr9Kviv/wAkt8Y/9ga8/wDRD1+ap60AJRRRQA+P71W7ZsOKpp96p4zhxQB0VqflBq0GIIA65qhaN+7FXUI3H3oAuxt8ntUwfABz0INVYm/dn0qVsBRQB9OeBbjzdPtGznKA/pVLxWQ18wPHJ/GofhZN5uh2LknIQCpfFzBbiRlG4bskZ6UActLcRpMkfHJ/Gpw4MyNkBc8k1n6kyvMnl9B1xSXUh+zqR9764oA6vTbgKS2c4ru9AcTWDAnPcZryXSr3J55Ir03wlLvtipOAQDwe9AHkvxPh8jxSSBgSRg/XFYlqRgk4PFdh8aIDFe2VwOMEof51xMD/ALnOODzmgB90QGJXv+lRqVZFDDjvUJkLkgdqaoI4zQA27G1CDg+9Zsu1oz1HFXrpgUGSeazHlO0gDp3oAyp+WA6c1GDz0ptyT5o570KecdqACQ8Vm6geK0JDz7VnahyB70AZUvWmnpntTpPvmmMcA0AQk1HIcA1IwxUEp4FAEVFFFAHp37NP/JcPC/8A10m/9ESV2n7af/JU9L/7A0X/AKPnri/2af8AkuHhf/rpN/6Ikrs/21P+Sp6V/wBgaL/0fPQB4EP6UUoo7YFABQaM+tITQAlIT2pScUIpdgBQBLax7myRwK0olwBUcEYVRVoAAcCgBVUu+0VqW8exPaobOEKuW71bT5iPQUASQLubc3T+dXlbpjFVrZZZ5Fit42d/Rav3Gn3toqNc20sauMqSvWgAj5UGpDKEXOOahhbBNSzYMJJ65oAqTTMwJbpXu/wM8L/2To8uvX8YE9yB5e4cqnb868r+HHhmTxV4nhtiD9jhIknbtgdvxr6P1i6it7dbWA4ghXbhRwcUAYmu6izu3IDPXPo3mScdBzmor+7EkxyTg802F/lAPfrigC/bob2fb2XkV6D4bthbRG4Y4VB0rmvCmnmVskcEc1b+JniCPwz4bdI2H2iQbVUdyaAPNPjP4qOp6h/Zlq+YkOZCD39K4KC4MEKxgk7uDiqW+SeZ5pSTJIST9annUK6DOSKANVsS7fLYcdRSuNoAxz/OqJBiKsCQ2KvW13HKuy5X5uzCgBFI3Dfz+NK8jQqQ3IPb0qdbXgyI6uB0qrdMSDu4NAEAh80+ZGc88g1KYSy4K8n1p9shWMMpwxq7E6yuI3ABUfnQBQxsGGBFXYZvJwZMEEfKaaYvn+YZQVHcMGbCn5fT0oA+v/BB3eC9APrp9uf/ACGtFN8C/wDIkeHv+wdb/wDopaKAKXxX/wCSW+Mf+wNef+iHr81T1r9Kvit/yS7xj/2Brz/0Q9fmqetACUUUUAKvUVOvUVBUyHpQBu2XKL9KuKefeqFnwi9qujg0AW4jlMe9TErsqtAflNSbiUYdqAPffg3MH8P24P8ACSMVq+KRtvSwH8WTXNfBCYHRdufuyGum8TBXlbglgdp96AOO1Mqk7bR8p71WupgIRGAeBzx1p2qPsudjHcvUADpTLoqltvJG0A4AoAl0Nla5bPc9K9P8Lz7ZPLGRx37V5X4dwZGbeN27oa77w5dYmwex6n0oAg+NVqZtEE/O6J1bpXk8MjCJM9VHSvcvHduuoeH7lGPBjOMc4r5/tpWCspPQ4NAE0j4m3IcZ61OrEn5D71UGDyCfpT0coSQOKAGzZOQcEdc1nyqULYHarznNVLgAoeegoAwLo/vxSDPall/159qQHHSgANZ9/wBB6Zq+5xWbeknFAGZIcuaY/SnyfeJqFjQA1uKglPNSmoH60ANooooA9O/Zp/5Lh4X/AOuk3/oiSuz/AG1P+Sp6V/2Bov8A0fPXGfs0/wDJcPC//XSb/wBESV2n7af/ACVPSv8AsDRf+j56APAR0o4H1oGPxpKAF7UhopGOaAEPNXrOHAyepqvbRb2yRwK1YkxxjigBypx6CrNtF5kg44HWmKueAOvatS2gKRqoXLnsKAEbgBV64qzZW8t3OkFurM7nAA7mmTQNE4VvvHqPSvYPg3pFhLbXN48aG4iYKrOOlAEnwr8KpbxtLexbbwttQNjI98eld14i01J9ObTri0idWQ5kRwdnvVrXdNt8ILDi4m4MqHlT/hVjT9ElhjQ71kmkAT5jk/jQB4L4n8KS6MWkWTcqjdtx2+tc5O7MiRopZ2O1VHUk17n8WrC9tfDVy9yLZI4mVVxncc+lcX8HfC41jWzq16p+w2JG3I4aTt+VAHp/w48OL4T8IL5gA1G7w8h7gnt+FZ3iC/zK0MbnC9Se9dH4n1Ly7dipKt0UeleYT3e52LcnPU80ATO5Ox93zFuVrW0q1M0iAfMM8isW2R7ggBcYPbua9D8K6aS6MQMKRjigDptHto9NsnmfgKoNfPPxG8RHxD4mmO/NpbEqhHQn1r1X4y+KU0TRGs7Z8XU/yDH6mvn23VvLIPJY5JoAsRAI4bOUx6UzeWfcc8VLKQsajPJ6VWTOT9aAL8bpIFL5yOnvVgRh8sF4HGazyRgYrSjz5C46kc0ARtcPHlV+6O1LJc+ZtxzntUbDBYEVVhJW5Ddh2oA212mBccetNRGGWHJqESE8r0NSRPwcH8KAHi6MahJRlTUF2F2lkbj1FNnYHoO9Z9y5BJDEYoA+0/AOT4F8OE9f7Ntv/RS0U34end4B8NH10y2P/kJaKAK3xW/5Jd4x/wCwNef+iHr81T1r9Kvit/yS7xh/2Brz/wBEPX5qmgBKKKKACpUqKpUoA3Lb7iH6VdHJqnbAmFMdcVcU8A96AJoPuE+9SKPlIqNOI+M09T8tAHsHwMlP2O4TP3Zen4V2/iMlbs7MZzj6ivO/gXKBc3kRzwwNegeJyUuy+Gxj1oA4fWD+/YjkbtoqjNOskJjc8U6+uBJK2R8u7v61SIy/zA59aANfQ1C3AQKeeVrstIBjvEVweR09q5Tw8v8ApO52wQoCnGBXVRv5dyGBDEHAoA7CRRc6dPGQD8h4r5wvofsuoXcJ/wCWcjD9a+iNKuAyshIy+QOK8P8AiHaiy8WXGBhJQHH1oAxI8gZqQt8vGelV4mwMUSPxhRk0ASMSB1qrOfkznrQ8mBg5qCR8gkdqAMqT/WsffFIOppBySfc0UAJIflrNumA3Voy9KzLnktQBnzHn61C3U0+c84qPrQAxuM1A3Wp26VA3U0AJRRRQB6d+zT/yXDwv/wBdJv8A0RJXZ/tqf8lT0r/sDRf+j564z9mn/kuHhf8A66Tf+iJK7P8AbU/5KnpX/YGi/wDR89AHgNFFdL4I/wCEP+1XP/Cdf8JB9m2DyP7H8nfvzzv83jGPSgDmj0p0EEs7FYY3kKgsQoJwB3+leon/AIUgf+ik/wDkjXqX7OafDRfiNC/g/wD4TEap9mlx/av2bydmBuz5fzZ9KAPm22iCp9KuxqMV9p/EaT4OHzf+Eq/sF7rkP9lGbjPv5Pz/AJ18y+Nl8BzXWPA8euqd3P21k8rr/CPv/maAOVsYed7Dgfzq6jMHEikjHQ0BdqhFGBQql2VBxmgB8MU11OFiUu+a9O8Aq+kapGuoO0SEb9pbAPHf1p3w20jThF5l1bme4YfKh4BOegNdl4h0Fp547yFhCnlEMgXcFAoA6hLlLrUrY2i/6ogyBPmz6GuoIjijmklkVYiN7O/GwV4xY+K7vSdcs/P8oQ+XtjZflDjsTS/Ebx5dSWB06zaIG4GZpEOePQGgCp8V/Ez+LdUstC0kmUBwnHRj616ZoWlW/hrw7a6dCQDGuXbpubuTXA/BDw4SbjxHfJlVylvuGd3q39K7LxDdTPbu3AB4wTyfpQBzvifURPIY423Kv8WetcrGUmnYscBT04qxqU2C4GAT145pllGJiAg2rgDgUAb3hq1M9zznIOfpXp9t5ek6RJdTEKsa8Vz/AIK03y1LsvLdOK5f45+KxY2a6PZv+8lGGI7DvQB5N421ubxD4mmuCS0SttjHoKiaMQR4yN+O1RWNrwZGbjHWo3fLlmHA6D1oAkj+YinTJ5bD1qOPqrdD6VNcOSoY4oASPBfBrTQ/JweMVl2i5YE9etaBZUQ47igCvLKS7Barx8Ek0sjfN15NKAFQ+9ADopWUkryKlM52fLwTzVQHHTpUMs2M0AXGuDtHmH8azLu43MQOlQzTEr8xqoZvXOKAPvL4cf8AJPPC/wD2C7X/ANErRR8N+fh34WP/AFCrX/0StFAEHxV/5Jf4w/7A15/6IevzVbqa/Sr4q/8AJL/GH/YGvP8A0Q9fmq33jQAlFFFABUqdKiqVelAG9akiCM57VcA+XNVLYZt0+lXBwntQBJDzHg+tSA5OKjT/AFQxRHnfgck0AelfA8sdevI1/uBsV6h4rgnUu6x/LtIx15rzn4EWrprd7cMG2eUBgD3r2bVmaW2l3IOVwARQB4ROW38jDd6SFjI7DG4DOfatjxBZLHM8sBVs8sg7Vm6cu6RnBXjqDQBvaOPMxtBXJ4BxW+hYEZcZHXFc/aXGEhwMAHtWv5/yAN1YdqAOg02Yb4nDYAbJ9hXC/GS223VrcgZzkEj0rqrK4BQIOnesv4lxC88JCbrJEf5UAeW2cMl3cRwwruZziuittNtLO5MV2rSPzjbn8qxNIkktLV7qFxu24+hr0TwpcWi2cEmoSK94ykAYyeaAMG40K01GF2hUo6A/Lgg1wV6jW7yROMEE169quu2dioYRASk4KdM++fWvMvGmyS7+0wjCydR6UAczGf5mn1CpAx9amoAjm6Cs2cnaT61pTH5cVlz/AHD60AZk33qZ6U+b7wpjdKAGt0qA9amfpUJ60AJRRRQB6d+zT/yXDwv/ANdJv/REldn+2p/yVPSv+wNF/wCj564z9mn/AJLh4X/66Tf+iJK7P9tT/kqelf8AYGi/9Hz0AeA0h6UtITQAsa73ArVtS0atsZlyNpwcZHpVG1TPNaKADAoAnjGFHHJ6Vr6fDsjLEc1Qs497g9hW0nACjpQAj7QgORk1t+DdCn1fUoiARAGwWxxWTaIJblFKFlB5Ar2v4b6AlzdWkUE6IhDeYm7uPWgDqNH8NF5LbyLeJkh6SIfuH1rpEtEm2RRpxHu3luAxqzqanRFtxEVKKMBFPB96m0yaO+ikmZZBz8oCnIJoA8o+LeixSfYTZ2+2CMFXZf4W7AV5po+lS65rNppluGaaV9rHrtUdTX0p4402C2tUFrInzLuYFuv/ANeuP+GPh2HTJdQ1q5XbJOSsWRyF7kfWgDqJ/I0TTrTS7QCOGJAuRXFavqYEjNJ84ByBVrxPqu9nRGYgfrXJiUlizt8xPQmgBtwq3DCQp9484ra0CwM92kUSfIDz71mw8yMwXcowAD2r0jwbpwit/OcYduce9AGzNPDomiS3EhCCND1r5W8Qao+va9c30rEh3Ijz2WvVfjv4mEVvDottJh5OZMHoK8WgJLBVOOOtAGjDIwG3qKrzOWkVQMDqasRDaMHrjmqeQ07gEegzQBZV8g469qkYl4V9RxUMUXl8mpIPmlweBQBctwI8HHNOlbjFNOUbBqCZiq9ck0ANY5apJThVFV4z1ZjxUU1xknBzQA+eRUXjn2qgzlj83enSsT1qtI+CRQAyZwTgGoGIxSMepNQSyALz0FAH6AfDT/knHhX/ALBNp/6JWik+GBz8NfCZ9dItP/RKUUAR/FY4+F3jA+mjXn/oh6/NUnJJr9Kfix/ySzxl/wBga8/9EPX5q0AFFFFABUy9BUQ61Mn3l+tAHQWwxGo9qstwoGagg4yPYVPJnaM0APXPljsK0NJgSXczHkc4qpDjMYfkVuaZaMHaaLBToQKAO1+BVxIfFVyBvZPKIxnjrXs+rzeX5pk+VSp4NeZ/COAWetMjQYkePJYfWvQ/E7rhlcbsjgY60AcBDpkpuZ7iAGUDl17AVma3o7afGt3bAqj8vH/czXf+G5rWNHWI5ZvvAr0rG8UQCa2uzIFZD9wg4FAHC20h3RNnjvWyJ97qAQBtGKxrVV8xwvbgZ7Vu6Xauu2SVTkf40Aa+i2r3srqm7g59M1vap4fE2g3EBYsWXBHvSeF7lZXljRfLCn7+M5retmSK4MDSFhIcjmgDwSx0ueJvsOwrKjkEnoa67w9Z2853XhCSJJs446VoeNc6ZrIMMSyCQ5PqM8VwXiK5u9N1bzo1MSAghlJwfrQB3OtaCk9lIbgxBACwYcs1ee3Nmtwjxzpt4KALz+Jr0DwzqcNwiyTTpKqphgV6Gqt7e6fb3Vy6wQM7nacd6APD5ozDM8ZzgHAJFPjORWv4slgmvnMCqNpxkd6x4j1FADZuKz7kDZxWhN0rOuPumgDLmzmo2qWbnBqFqAGv0qE9amfpUJ60AJRRRQB6d+zT/wAlw8L/APXSb/0RJXZ/tqf8lT0r/sDRf+j564z9mn/kuHhf/rpN/wCiJK7T9tT/AJKlpX/YGi/9Hz0AeAU3qadSxDLUAXbZcAVcTqKrR8Yx1q3EN0gFAGrpqYXd3zmtZY8IM96pWK4YAdhWoVG0dRQBb8Koza7HGpVN38TdBXpXhLzbbxNbyWcbZz83zfK2e9eT28htblZV5wcEe1e6eDtJhWKz1JbncDGpVV6H2oA7carNbX1tDqOnsyO3BPaui1C7jk08/wBnp5JPJwOB9ayNO1VJ0YarcRr5THYZABn05rg/H3jlUhkstLcJb4+Zx95zQBp6nq48R61ZaLatvZD+9mTngdRmtLxPqUVjCYLcqIol8tFXjmsD4Z6c+jeH59cv123N6T5W7qqev41ka5fNcTvkYU54/rQBl387zzFycKB1z3qlBAzzBpHPy84pjHdJhkI54HatDT7Yz3CADlmoA6Pw1pZurpSR+4Tk+5rvZbuLSdHu9QmO2GFTj3461T0uz+y28EEI+dsbsCuK/aB19LLTItBs3G+b5pgD0FAHifiDVZdc1m61CcnMrnYD2XtUVqoAGfqaqwKWZVHIrUgQA85xQAhcYYjIAFU4ULNn1PWrl4vlQFVH3+/tTbYbQM8igCZCNpUnJApkP38478UgJWbPapYlAfjoTQBZfkbu3Sq1ywyABU9w3lggfdqg7lh05oAjuZdse3uapgkVNdEcDvVVzg0AOd8KSTVVmyM+tK8m49OKhkbAoAZI4ArMupgeB0FSXU3VR+dZdzNjOKAP0c+Fhz8MfCB/6g9n/wCiUopvwoOfhb4OP/UGs/8A0QlFAB8V/wDklvjH/sDXn/oh6/NY9a/Sr4r/APJLfGP/AGBrz/0Q9fn14I1jw7o93dSeKfC//CRwSIFii/tCSz8ps8tlAS2Rxg0AczRXqv8Awm3ww/6JH/5ct1/8TR/wm3ww/wCiR/8Aly3X/wATQB5fbQyXNxFBAheWVwiKOrMTgD862dW8O6zoF6kGuaVfafIWwFuYGjz9Mjn8K9G0Hxr8MzrmnCL4Vi2kNxHtnbxHcsIjuGGIK4OOuDX1L4r+Mfw70xJLS/1uz1J2GDbWifag3sSoKfmRQB8QQj5iank5ZRmvUviB448A655o0DwIltMxyLszfZiD/wBco/lP4mvLCRlaALEoKeWydua1tLvDFIhMojRmAY+1ZG8FMN0pkcTyPhOcc0Ae9/Dcxx+JUEcnmxvCSpzXceIH36l5IUFiuMk9K+fvhteXkXjTT18xiMFcDkdK9P8AFmuXdjrUrQqv8IG4UAbtvHFZQukbBpCT0PQ+9cv4nvPIsxbsd5YcgcEE1kX/AIs1BxINsKsed4GDWA17LetuuX3OW6+tAGnpMKm+RJHGM5JP8q9AjtYriRIYQwReXx3rz+zLLcxnIUhhn3rv7a9C27XMfyyg7Si9+nNAGtawx6dttokJEoxvHY07UJFiuoRHKAcYyBWUNTl85I4YvMMgwSexra0+MiHFxGfMHfGcCgDgvE+j37Xcd3JO8qSPtVc0Xtt5Vskd7ai5gJ6nqD6V3HjKeGy0UXRI/dfNivK9b8f2RtTHbrJJJIpU5HyjPegBbs29lqUSWbiOD+MLyKqP/Z00UpMpMqkufcdq477SWB8tpWQtnjvUGpefBFmNZI0kHIbvQBQv2D3k23puOCO9Rx8Hmq8Jyzc81Oh+agBJuDVC7Hymr01UbzhetAGVN0qJqnl6cVA1AEb9KiPWpX6VEetACUUUUAenfs0/8lw8L/8AXSb/ANESV2n7an/JUtK/7A0X/o+euL/Zp/5Lh4X/AOuk3/oiSu0/bU/5KlpX/YGi/wDR89AHz+elT2y96rnrV23GFoAmUkHPSr9kpzuqpDG0jfKpNXbf5eD2oA2rE4UsepFakKbwGkJUHoMdaoaLazXkuIY2bHoM16MNDs4vDkRuSzXTPuUqc7R6GgDiZYRzySPp0rpfDniHUdPsktlYNbISYw2cg+1Mu9OH2QyMEjRxw3cn2FNjsCxRYmV0A+83y/zoAfreu3utSb7y4EflHCqvArU+H3hefXdbjF4x+yRncxJ+9/8AWrKg09HnSPBlk3fdA617JZW48MaGkW0DUrtMMe8Seg9CaAI/FmqK84tLZtlvbr5aD1NcNqN07yFsHA4rZvY23tITyRkE1kTx/uVycGQ9+TQBFao0kiM/K/3cV3vgvTkvdVhZU+WPLEY4rjrWJlLB2DHbwBzXq/wwszFpd9dsORHheOhNAGjcTxaal1fSMBHEpP5V8leKNYn17Xb3UZ2JMsh2Z7L2r3P43642n+G00+3bbLdMVOPTvXz7Im0oPwoAnslAwTnrWioAAyKrWa5A5q+sYIy/TJoAoTEtJzkjPSpmUKuV6UgUNIB6GpJMKD6ZoAgxmrCr8gA61GOG2+tWHYKnSgCpdMSu3vVaPIQkninStmT1zTJiFiPPJoArTuGkPoKpO5LEdqkmfBwKrk9SaAA8CqF3MQMA81NczbUPr2rIuJjzk80AQ3Epqg7bjT5pCxxUNAH6VfCf/klng3/sC2X/AKISij4T/wDJLPBv/YFsv/RCUUAL8Vv+SXeMf+wNef8Aoh6/NZvvGv0p+K3/ACS7xh/2Brz/ANEPX5rP94/WgBtFFFADl61d08ZuV9qpJ96r2nD9/wDhQBtQ9G+tSdxTIhhevWnqMsKAJE+aRQ3TNdPo2nrIjZHzHj0zXLj5WU9wa7fTbuJ7MzQEblGcDrn1NAGr8NbRF8b2KquzYzFt3XpXsWp6XY6rfzmWIB4j1/CvMvh28eoeKrFxxMrEEg4zxXrF6Vtr+4Qqdpxn86AOV1bwpbXNvthMKSAEAYrz7UtHbTpBChMkgfBCivYraSCV52LLiMYwetYkUMUs86LArOrbg+OcUAebYkjGJAQwPeuk8PX7NcrDOcq5G0k1e8X6escQdIVAb+LbzXL2zAoPNB254PegD1qRIJIWCKiyRgYxV6wZCoDMyR7Tk9Qfxrxd9VvreTNvM6gHoTnNPuNe1KZDFJcNsIwFXpzQB1vjbWotT0240vTQZjgr5gHX6V5Tonhd5p83jqu0/cPU/WvXPh7pMNqA94u6U9iOxpPEmjWy6izW8apI2SoHfPUUAcJDoR8+EC2YwMQWGMY9/pVjxpaQR2iwmJVd03ZPAGK2NW1dNJaCCQ5lQfdB5A7ZrgfGuoNeTW4hlaQKDkdcZoA4hcpO4OOtTA/NT721a3ZGbq9RJyaACY8iqF3kjk1dkOWqnd5IOKAM2U9KgPWppeoFQnrQAx+lRHrUr9KiPWgBKKKKAPTv2af+S4eF/wDrpN/6IkrtP21P+SpaV/2Bov8A0fPXF/s0/wDJcPC//XSb/wBESV2n7an/ACVLSv8AsDRf+j56APn/AKsKvJwox6VRH3x9avx8bM9ARQB0ek2oFuqlSWk4NdZpHgYSp9s1G/igtkGWUDLfSpPDNqq6WJii7iOCRzz6UzxDelHW1jZgqgZBPfFAGubyKRUsNMjEFmpx8nDN7samurhHu4bS1P8Ao8ICszHksax/DkTSu7jPyxsSSOBTkZm8yRBkK4A7A5zzQBtXUour6NBLiK34Ax8vvUsCS3t+1vaoCpfCepH+FRWEJmhSGNdzynJI7/Su50jT7HSLLa5xcyLuLnGSB2oAk8MaVbaFI1/qLLNdniJAOF96vXc/2ud7m7bJbOOc1z3nm5aWVjheTweKfqF0fIUMxxjgj09KAH6lceZt/ukED6VUtFM1yFyBgdKijnVgC3KYwKvWsqxIZDjnAAFAFuxtV+0HI3HI/AV67pAWx8DXNwflMmP0I/8Ar15j4fh8+6/d9H4ye5r1PxTG1n4Uitox8scDSN7nHH86APmX4napJqviXDP+6hTCr6VyBjLNkjIFamtljqU7ZDOOGI9az0BzuzjNADoCFbb0rSRcwgZ5NZ8iFHDEZz3FXiRsypHpQBUXIY88g0THkZqaVMYkHQ1BLyxz2oAAcuD6U+Zztb0qvC4O4Zp0zYQKOpoAhUgPuaql0+WbHSppWwpz1PSqM7/KFPegCs55JNQSyBVPrUzHAJrNupCWNAFa7mwOTWXNJnk1JdSZcjtVNjk0AFA60lKKAP0p+E//ACSzwb/2BrP/ANEJRR8J/wDklng3/sDWf/ohKKAHfFT/AJJh4w/7A95/6IevzUbljX6VfFf/AJJb4xx/0Brz/wBEPX5qUAFFFFADk+9Wjp3+sZjWcn3q0rH/AFbH3oA1UPIHapk++ahjIKAnrUyE/TmgCRhWn4ault9QSOUHy5DhiKzGbOaASGDAkMOhoA968Dpptt4tsks0xKUZsZ9q77VD9qv3hm6ZxketeN/A6/hl8Vxxz7nufLYh27CvXLmbzNWIDAuuWz7UAczqtjPp9/KwYhGxzn5SKs2lvLdwO1pLjaAcjvWtqm29tZYHwQB1Poa5GGO70S3u4rZ3fkkKSf50AXddWSHS1kunAcjlSck1xDcKzE4Pb6U/VL+4mCwyzF2HJHbNVY2Lpg5BI70ADAlSMc5zmtLwzZQXOobbnP8AsnsDVKcFVX5SCODzUcN1JZzCWInPcUAesaZazjKTP5ew8Me9R+LpILOwW+P7x0ONymuIXxje3csKFwnRWB711N4gu9Ke2fZmT7vtxQB5C9nfalql7JO7FZMuGY849KmWG0hjMcqEyMnH1rb1G6/sqWZdi+YBsyeM8Vx+oajLasGMYO4E5zQBR8R+XtjO7L9MVjL0qO7uTPIWxgZzTlbKAjvQAHvVK6PyknrV08KaoXR+U0AZ033hUTdallPz1EetADX6VCetTN0qE9aAEooooA9O/Zp/5Lh4X/66Tf8AoiSu0/bU/wCSo6V/2Bov/R89cX+zT/yXDwv/ANdJv/REldp+2p/yVHSv+wNF/wCj56APn8ffFaNsvmSRr6kVnD71a+jgPexCgD0y2mcWMHlHGzAYVgXjvNcu7AZY81r2u42MjADawGD7YrNmTEg7Ed6AOs8Owxw+Gbq5aTDE7NoqnAuyJIzlWlbqf8+9QabO0ekzQNwC4PNXZZEOsW4JHljINAHUeHreKxS3VkLSueGJ65P6VBqF/Lc61KzqxjDlQo7AVZshJLKt0mAkanAHOKpWwKX8rZIc+vcmgDXsQFHIJXaflPvWbe3JDNw+3HANb/8AaUUbBbyEFCn3lAORTljtrlowsSMp6HpigDnrScHB59D7mr8O+aZUXHzdM1am0qKOUum1QTnAqxocW+5DBcbT8poA67wlYeXdQq7DJbHTkmuy+KeoG30W5ijGfk2sOnGK57w1GW1OF2OUDAkk9Kf8Sp/tSXUZJYZCkD09aAPAY7FZ3eQj5pDnHrUEWlyOsxEWRH94dwK6uy0U/bBbOf3Un3JPfsK0JLf7PdSwxRgzzQvECe7KOn5ZoA8/lt0MG0E5HSqrKUwhOa0xEyyFXGCDgj0NVbuEK+R1Y0ANKbbcBuT1rPu3xz+la9vjaFbr71l6nGpLgcEc0AUrc/rUtw/fvVRSY2wDTrhwVzQBDK55NVHbccmpLh+APWqsr8Y9aAI7mXC4BrLupNqk1ZmbJPpWRdy7nPPAoArSt+ZqKlY5NJQAU4CkXrTqAP0n+E//ACSzwb/2BrP/ANEJRR8J/wDklng3/sDWf/ohKKAF+K3/ACS7xj/2Brz/ANEPX5qnrX6VfFb/AJJd4x/7A15/6IevzVPWgBKKKKAHJ94VqWeRB75rKHBFa1t/qloA0bf5o+eo5qZetVrY4Q1bUZIA70AKKM8igbRwTT0RCxO4gdiaAPRfgTbNL4ov7vB2W1sefQk10c3iF49ZmyTycbxS/CayOmeANV1KRMSXkm1D6gDH9TXMvCyXTb+Tk8fWgDtdP8SW0tuYppGBY8Z781Y1bW7ZYdttgF87h1NefWUBJYS43LwADV+0hZjICpZgvSgChKWeQupO4nqafbzLuCuMEcVdMCuoRgA684zzVREXEm4Z980AXpyGRWUfXmqUrBcjvg1OxAt1yehzjvVOcZkBB59qAKNwu18oxUg9a6Xw74iltpFF03mxgcA9sVhXCM0DHgkVDDEHAw204zQBpfEm5S52Xtuw8tvvJXnF7fPMu09K7eULcWk1vLz3XNcDeQtbztG+eDwaAK7jGKmiP7uoSKfEfmx69KAJJDhRVC5P3qtuc9ap3B649aAKMn3zUZ61I4+Y+9RUAI3SoT1qZ+lQnrQAlFFFAHp37NP/ACXDwv8A9dJv/REldp+2r/yVDSv+wNF/6Pnri/2af+S4eF/+uk3/AKIkrtP21P8AkqGlf9gaL/0fPQB8/wDRq2/DoB1FM+hxWH3rU0ibybqKTOMGgD0fSz52k3YHWN+KzpBvfcfl9RUGjXwtNSuIZXxBdKGXPrU08ixPJvOSG4zQBoWcm+OWKQYBGV46kU65uMXcbHI5LDNYgvh5oJcgg8V0V21rc2ZfaIpQAUPXd6igDrvDE6XdrNGhKueR7n0qxcQLHfLJ8wKdV28ZrH8Jy2wtNkhPmA9F4NelaZp0N7ajzMeZxuGece9AHFTwzSmRypAIzgDoPakgkkiCCMkyEfeJ6V1mqWEkEm4L+75GFHOPpU2i+GFvo5bmXMW0fIrDBY0AZOnTuZFivRuQ8ZBrsdK0uEKqwKX3HAwOlUotH+xSFp495z93HQf0roLPWYNNjdbKJRcYzuPagDestDbSrY3Vw6iQqfLh7nPc1h39mt6DI5cuBkntWJcatdXU8jzztLIefmJq/pt8qZQyvgkjHWgDDfT2FwY4E4PIDDgVheNLj7DqdtLBxJGhLf7xGM13l4xjmQBTmThSOozWVrHh+01O3ljRA88ed0gbLA/T0oA8hMhd2ds5Y5596qzIXwB2NXtcsZtMkET8/wB0juM1WtZFZjnpjkGgCKVdiMSPfNZEjFpWzyOa2rsfI+O4rEQbZmVvuk9aAM18+Yc9KjnkCipr75HBH3TWbcSA5waAGzPuI9aryPgE5p59agmOSFH1oApXsnlwk9zwKxnbtV3U5t0oQfdT+dUDzQAlLSU4CgAWloooA/Sf4T/8ks8G/wDYGs//AEQlFHwn/wCSWeDf+wNZ/wDohKKAF+K3/JLvGP8A2Brz/wBEPX5qnrX6U/Fj/klnjL/sDXn/AKIevzXYYx70ANooooAK1LQ5jXPpWYOtX7c/ulFAGpZ9Dj1q4rbeap6f80RP4VaJoAfxu6Vbgga6ngtbdC0srhFA7k1DFGOh+8e1el/CrT7S21OTV7qINHYR+YGbpvPTFAHb67s0Tw7pmixfct4wJCP7+Of61xVyuL4YHHrWxNq66tfTPc5JyXBA/Sp4EgaU+WuXK5XdQBzcYCTO6A8dBVy2S4GCFALnitnT7B55ZzNFjA7DFWJNHc3SMiuUZcDjvQBym8BpWc/NnOKgkJaI5Ug9R71o3VjKlxLCyFtp646H0qJ41eJR8yupxtNAGU9wYSFZQyEc+uakDLJIrIvBHNVtQ++yspGOmKSzDKjbSeo60AaEUPyupUnnjFV2tnUctg84NaSzQggKduV59zVW7QkbU5yeDQBnzwD5zu7ZrndYtVlAORuPQ+9dTcRPGJQwxx0NYl2o2gD6n2oA41w0b7XGCKM45rWv4Q7c4PvWTKpQYNAAT61TnPzCpy+Riqs7fN9KAKzfe5NMPWnP1ppoAa/SoT1qV6iPWgBKKKKAPTv2af8AkuHhf/rpN/6Ikrtf21P+Sn6V/wBgeL/0dPXFfs0/8lw8L/8AXSb/ANESV237av8AyU3Sv+wPF/6PmoA+fWFTWr4bae9REZpoJU5FAHRLL51uiufmTpVl5JZEBLZ4x71kWcwYD1rVhkGAD0oAVFI9zW1ZTiaABsB0HGO9ZsSg55p4UxsGU80AdNBN5aAoPc+9dZ4V8UX9hdB1XzbcD7j8/rXBWlzmMhuO1b+kJ5kO1Zuc8DPagD27QtXtPErGOGRIblQBsY/ezXUpaXNrdgP/AKlCMkjg14jBp11CizQ7kcNkSICDXXaJ4rnU+Ve+YV2ldwyQaAOsvJGmuZnfO1mOB2pg0h5cyxhdrep5FU9Onk1UeXaF3Oefauns9LmVQshLYXgUAcrLaP5qKgC85NbNjph3hlXAAyR610MekiZdrqocHt2qLUGh02Nme4RpVH+rjOc0AcZ43vzawi4HyOo2ovctXDDxbd6Vb7NhkuWXPm5/nXTatFc63flrmPgn5F7KPauQ1PRJH1FiwYw87GHQgUAc1q2o3eqTm5u33yN0IGMc9MVVtlxcPg8GprsGCWSPoAehpliA0u7gEUAWJxncByBWTJEdxJ6dq3JgEYjAwRVC7xjAHNAHO6iNqlc81huORXQaopZs1iTrsPNAFadypwDzVWaQIjO3QCrE2MZI5rI1eTG2MfU0AZ8jFmYnqTmmUUUALSgYpB0pwoAKBRS0AfpN8KP+SW+Dv+wNZ/8AohKKPhR/yS3wd/2BrP8A9EJRQAfFj/klnjL/ALAt7/6IevzYf+H6V+k/xY/5JZ4y/wCwLe/+iHr8126LQA2iiigAq9bn92BVIdauQdKANbT/APUn61bAywFVtP8A9R+NXIQDKvp3oA0VgMs8MaLl2IGa76/mXStItdIgXdLIRLOR3PYfhWR4U01Z7i3mkBGG3ZPTFTySGXVriaYndvOCKALmkz+XdgSJ8r4XPXBrvrPT447RWZwCvfHJridEjE02GTIDD5se/rXWX2oGaVILdCI0wjMPrQB0Fl5fnPgq8BQexFWjforw+TGNhwCO4/CuXHmC5jWNiqHnrWrDI58l2wHTkn1oAy9ZJiu527OSx9q5e6uPs4k2hZPlxuI5rqtbYuC+zgEnFchqPJkRxhzyBmgDLnLzSNnABB4HWo4gUt93QqcmmMJVl3KPbHtWhFa+fE+4YAXJBoAjt0LR+cV4OcE0t1dMy+Wcg8kEdqv3aQwacrMcKpGFHfPpXOaheNK4MaAKOKALcU3ms6O4A7ZFZ13D12srN296ZGWYk8AikbDHG4E44oAxrhW3srKQB2NZuoRFYw3UV00oSbAfJfp9azby2TcV3DBGPxoA5ZzgVXlOTmrd7E0MuxwRiqEh+bFAEbHmkobrSUANeoalkqKgAooooA9O/Zp/5Lh4X/66Tf8AoiSu3/bV/wCSmaT/ANgiP/0dNXEfs0/8lw8L/wDXSb/0RJXb/tq/8lK0n/sER/8Ao6agD59pp606kNADoZDG+RW3C+5Fx0IrArQsJsrsJ5HSgDoLJt3ynrVtl2vz0rJtHIcc1q7tyA0ANDDOM1p2E8kcsWG+XI5PQVmle9dB4N0k6zqQikfy7eMgyOfc9PrQB9D+A7yxXSreSYGUuO64B/8ArV1aaVo8zGUaZC+WyWB5rgr94QiWOnAJDAFTK8GpLC+v4IHO8sd3HNAHo9vFpaKBDCYMcHYBSszMGEF5t4/iBFcRaavcy586GTaBgn3rcs7uGRcOzL65FABJFcSyqZL0kZ5AJNX47CxuUA3Mz89eATUBuLNCQjMx9hWNrGq3kCqlrb7c9HY8gUAWtcWa2tTb28MZd/l+UgbR681x7xLZvJbtMXgcfIF/gNadpdTu5kui8ueCw9a0ZbCx1C2JjljSRFJC45oA8a8SWfl62UyoU4OfqKoRRCC6dc5U8g12Gr6W99qiFhhtpKjHXAx/OuTuYmicLIpWQE5HcUAPmIPbPFY9y5L5H0rRlfDgdOKy5TuBwO9AFWdBIjA/hmuf1BfukfSuhnI64wM1j3yct9aAMhlyRntzXN3rl52J6ZxXRyttRvWucul2ufrQBXooooAcvSlpBS0AFFFFAH6T/Cf/AJJZ4N/7A1n/AOiEoo+E/wDyS3wd/wBgaz/9EJRQAfFj/klnjL/sC3v/AKIevzYb7i1+k/xY/wCSWeMv+wLe/wDoh6/NhvuLQAyiiigBV+8KuxdKpx/eFXYRkUAa1j/qvfFaVsmWX1zWdaDC4x2rTtfmmVAcEmgDr9Gnkt9pPQfKvvWjYxrNdkKygbtzZrLZiINq48tAM4pNGv8AGoNuUuozQB3tnpr21u0kDKyNz8vqas2ELK5f5sg9x3qlo187wvEpICjIAHNbNncPJblZgQRx0waAGsz+eoaN9xG4NjitzTkBIeUDKjG09zVeyhjeRmZn2gABal1SSKC3zkkj8PzoAqXMpupZsBQpGBxxise/0+zmkBkADYwcUkl62X2jIIwSvFQ3MLyN+6PsdwoApHQvPQPbspi77uDinXejS28ciqPlIHU9q3YGjjsBGzgFTyCOtXLP/SYX2AgJyCeaAOUutOafTEjLKZM/Jg9QK5LULCSJiAegyR1r1bWBaWj26yBS7fMRxXnmsXkP2p/KQgMxAxQBkG1IZjg8Cqt0vloXAGVrVW5QxjKfLjHJ5rI1BWNnI4+oFAGNJdFjk5H6Uy5cuQce/wBaq3G4EjpUtpmSaNGGRigCnr5BeEHltnNc/J981s6lN5tzIx7cViyH5zQA080lFFADJDUVPc80ygAooooA9O/Zp/5Lh4X/AOuk3/oiSu4/bV/5KRpP/YIj/wDR01cP+zT/AMlw8L/9dJv/AERJXc/tq/8AJR9J/wCwTH/6OmoA+e6Q89KTPFA60AFOjco4YdqKaRQBsW8oZVYGtyzcMOe9cjay+W/PQ1v2U3IwfpQBpSMV9jXdfDdAYJZA3DSxhx+NcLL+8jzjkCuk8CXBRZoA5DOwZQPUUAevxXbtJKsOC5fk/Q9q20k3GNXUIGOQCa43StQW1G2ZN05G4E+la1vq6m8QzqcHge1AHbJKkUQHy5J5Jqc3iiPCKM+hHeuWa7Eu472UZHTnitO4DR28NwrAgLx70AX7eWSWUuoAUcYxRdxvIQ8pKqo7nrUGnXEi6fuZAHL5A9qckzXm5WABPUdKAILPTXmkL78RDkse1Y2s3k9rrCiAAQ52gjo3ua6W/Y2FjJDEDubknrj2rntUtVSxtZ7lvLblmJ4wAKAM3xDrVjYyJ5K+dMIwGPbPpXAXlzJeXs08pGWYk7RxTNUu0uL6Y2zHy84XNRBgtv1w3T60AVrxj8v+z6VVY5AK9O9WM7oXZ+tVjgZA9KAKsjEkg1n3IDA81fYfM3pVOcDkAUAYF0MZ+tYOoL8/SuhvVwTWFqC8igDNopTSUAOFLTRTqAClpKWgD9JvhR/yS3wd/wBgaz/9EJRR8KP+SW+Dv+wNZ/8AohKKAD4sf8ks8Zf9gW9/9EPX5st/qlr9Jvix/wAks8Zf9gW9/wDRD1+bJ/1I+tAEdFFFAD4vvVft1zgVRh61qWqgtQBo2wI6DPQVoWylb2BhwN4yao2xw656Zrdt7VW3SSSBNvIzQB01hEtxBOx6YP5isewV47xip+tbejHyNPlkLApJlR78VRskUCdmPTNAHdeDZ7Z/mkOW+4wx1rpEQPIVDYJGASK8+0y6igVHgkw27NehaHqlteqhZl3CgCTTFZJWGAeP1pmuwkpGrkq744rXghRHD43Ag9BxWvZ6ZHdlbu4A8uPoGFAHnMNnFExCja6cYb1qvPLdO37s7VUc4HU5rt9W0+GWZp1iC7ck89ax7eBbhzBHGT14zQBw91JefaC6bsM3GBnJqRNUv41MUcmwscniu6utOMUAwkSKDk5HIPtXPzzQvDJ5UeWHUkUAYcMN7dXQNzISwBIJNczMzeeCVHyuRk/Wu9do2+zyBXAKlD27VxN/F5N6YRj5W5z9aAKql2ztz8uR+lRXbN9lk3D5SvFaqx7lmJxgBu1U7uPbZ5boRwP8/SgDkr1eM9KNNyJgQM8Glvzlm9iaisSUlY5xgUAY94R58+P7xrMf75rQuj+8f3Yms9/vGgBppD0pTTHPFAETdaSlpKACiiigD079mn/kuHhf/rpN/wCiJK7r9tUf8XF0n/sEx/8Ao6auF/Zp/wCS4eF/+uk3/oiSu7/bV/5KJpP/AGCo/wD0dNQB87jrQetJTh16UAAOaX60YooAaeDWlpc+CUJ6dKzmp0DlJQRQB1kU37vntWvoNwbW4tZ4yQ6ybq5/TXV0YsC2P0rZEq+VasowAecUAeqQail3ftJtQMOVx3rWlQb4pMkAtyOtebrcsJVZGI4Fd3p9+JkiDjnbzQBZa4nWeTO4J0GBxWnDq8zWQibtyKpSSrOAIzgHg8d6hkUxIxYYC5x70Adlp979ocRlgN65GO1adsF81dvBU8964rRrxFdUnba2eCO1dZpSZllyxcY3A5680AacsmZSVAYMckt6V578XtZB/s+ztXHkyBi5Xvg8V2viu6j0fw6l3cEqXBAHc+1eKeLrk3Vvpt2RtUlwBnpzQBQjAVSFHPU1BJIWlCgnaOtPLnymZOvc1AihmAH3z1oAszkCFFA61WdSpPHFOckzAHtxT5QHU4oAz2++wJqvcDKH2qxJxKahkG5G/OgDE1CPIOB15rB1EfKK6S7GRXP36dc0AYjjDGm1JKKjoAWnUynDpQAtFFLQB+k3wn/5JZ4N/wCwNZ/+iEoo+FH/ACS3wd/2BrP/ANEJRQAfFj/klnjL/sC3v/oh6/No/wCp/Gv0l+LH/JLPGX/YFvf/AEQ9fm1/yw/GgCKiiigCWHrWta9B61kw961rPoaANOyhLlmY4jXqfeug05ob5ZIzuDKp/wDrVR04QsoSbIjx1HPNaUekXNtcs9md5HRge1AGjaK4UR5IVeMH3qN7eaN3+RiG7gcGtLT5tSDgXWkLOOm5QQf0rZFwiFQ+l3ceeAANw/KgDA03Tbua8REjJx29K9J8N+GrgRCR2wyE5UEdaoaFJHEyTtZznB4UKFH6muuttWSHBVUUEfcDdDQB0ek2kCRI12vzKPunpV+/uw8A2MoQcBFHSuOu9YmntsoSCO/pXMQ6tqlxqGwMyRq3R+hFAHoF+qXFi+8bS45we1YdtC1uxlwPKz170mmTFo995ersBwEx15q54g0m0v7ETpPOoAyAh6UAVWvor25CMv7rPAb1rk9d064tGdQp25LLt4rS02E2aC6mneSFGyA45b6Vpy+JLe5O7KKp+XYw5oA56xmna5tlOzyCPT2rl9bAbWJ9qjJb0r0ZGtbiHfAimJR24I+tcRLYmS/klVt67ueM0AQpbIsMqtjcQAD9TWXqkIaBlT+E8V1ENr5jshG3aTg4rJ1KIW1u4YfNggEcigDzbU08vcD2PU1TdvKhUD75BJrR1MbrlgThc5rLuGLiSU9uKAMWXnr3qm/3jVyXpVRvvUAMNRSHtUpNQMcsaAG0UUUAFFFFAHp37NP/ACXDwv8A9dJv/REld3+2r/yUPSeP+YVH/wCjpq4T9mn/AJLh4X/66Tf+iJK7z9tX/koWle2lR/8Ao6agD52pVpOtA60AOooooAQ9KQcEU49KZQBs6LMVmK9mFbcb5Xy8cZ4rk7WYxSK69VNdNYyLPIAOj8g0AdDBLlEfPK8EetdLpGoSPgKVUqwII9PSuUgyqlev9a1tGlQF1kXJPQ9MUAdhDdyosvQnrT1vvMUqzYGMgZrBS6Aj4PU4+tS28iD+IH0FAHTW9xGzo3C9Rk113hO9xdrbysSkxAU56GvO7HBkCyMNoPTOfxrs/DOwapAQM7G5570AaPx8k8qbRNOBwqxl2Hv2/nXmWqWv2jwo0ictaTBiPRWGD+oFej/H1RN4i02QZO22XcPrXH+HAtxFd2Ug+W5jZMnsccfrQBxlvKDCFJxj1pmSu5hwe1RTBobt4pD86naR7jinB8sRnIxQBJvAwT1HtUoc7sjo1QRj5WzUifcGT0oApuOXP8QNQSEhWxU/UPnnmopuUJA5oAz7gZU/WsLUUxn0rffkGsq/Tch4oA5ideTVar9ymGqkwwTQA2nDpTaUdaAHUUUUAfpP8J/+SWeDf+wNZ/8AohKKPhP/AMks8G/9gaz/APRCUUAHxY/5JZ4y/wCwLe/+iHr82l/1DfWv0l+LH/JLPGX/AGBb3/0Q9fm0v+of6igCOkoooAlh71oWbnNZ0XWrULFTkUAdLpcrbs4G0dzXURTG6hAjVlxxvFcnobGVtidScAGu6urVbC3g6AlRkDuaAK0N1JbsYmlbPX5Wqxa6nN5gId2C8g5rNdDJdHJzjoBWjZWFwyFlCAEdD1xQBvRapIvIAGcYzV2wupZJcZy5ORWN5ezyRIMnpx3rS0p/KZ0BGBkg96AOssJwW2SvgNwVxU80dqsJSKUSTt/EeiiuYlvxCUZ2YpjOQeadFqCJEdm4v2/GgCzdXEtvI6BQADkk8iqs/iy/jtFhjlCj1xziri+VewFZPlZlGcdTWBrenJA2RKCMYHagBl54mu54vKldWTpnFN0698xgspDxtxhuSKyIoVMp3EHjt3q/pFsrXrb+h9OwoA7K0gazy1tMXhOPkcZrXtpdNwTdReRL1JwcVykcktv8sbfuwMKTUTX1xgq/zcHOT1oA6q6msFlKx3URDnjnFcxrEqyl4ljDrnqpBFMku0B2vGh+Uc4qlcywohk+VF6HFAHm2tRSJfTISwAPesq5lAhWJSc5yxq94klDarLtztPTnrWPQBDL1qq33jVhzmqrd6AGOcLUFSSHnFR0AFFFFABRRRQB6d+zT/yXDwv/ANdJv/REld5+2lz8QtN9tKh/Waf/AArg/wBmn/kuHhf/AK6Tf+iJK7z9tDJ+Idh6DSYP/R1xQB87UdTxSU4CgABpaKKACmmnUjUAIpwa2/D8+26VD06isOrVhP5F1HJ/dP6UAekTooQupxuAYGmafIVfIY8g8+lMDCWyjOcgjNLY/JIQQR/hQBsrLmBhn3JFWLRV2KAQec4qnGw2MM5ziiElZFZidoFAHT2sXmITFlm6BRXY+F4mjkRmzknJz2rldNYQy28iNw4z7V3mjQ7tsyYCA5x60AJ8bkP9s6M4OftFkU/FcEf1rzq2vVguo5EyoXHGc16V8cXKaL4av8AiKVVb6HIrye9Ty7uZV6Bsj6UAVfGlqsWuJdRf6m7Tzlz6nqPzrNgxgkjiuh1GJ9V8OqVH760JdfXbnkVztu+4Y9RQBYUjtinSrhc9KgYEZx68VIznABHagCt82D9aikyUOKsL0ziom5yCMGgDPfrVC5UEMAK0JBhiDVSVcZzQBzd7EQxrLlFdHexAg1iXCYJFAFKloPWkoAeOlFItLQB+k/wn/wCSWeDf+wNZ/wDohKKPhP8A8ks8G/8AYGs//RCUUAHxY/5JZ4y/7At7/wCiHr82l/1En1H9a/SX4sf8ks8Zf9gW9/8ARD1+bUR/dSDtwaAIqKKKAHxdatxAthVGSTgYqpH1rU04YZn7jpQB0/hK3S3uSJiDNjcq+ld1dwi9sIZUAZ1J3D0rzKxuHhuI5Af4ua9AhhuditazARyLu475oAoLGzTuQeB0rZ0m+dWUOASgwc+lZaxyW8nzjO7mryQEbZoQVB6igDc8kXULu4ACgkYqLTmaS/RWQhByK0fD8ZnlKvFuB+9z2qHXtRtrOdY7R8KRggDkfjQBX1DAZNo7HrUdkJPNQJ0PUVTnu5J3iz8wAPNX7eUxlG6BuPpQBPb3hilcjk88Vl61cm42jkADnvjNS3k48wMq7SWOaoTueCBkkgYoAfaIrIpbpwK6GxtxGzBeCy4zjpXMrlmBHG49K6yKUokalQF2c5oAsXMWxchTjp9BWVdxF+SSoxipNSvniGC3bJGeKzZdTMsfGOBigBt2ySO3lPgDv6Vj3MpMRjblFBbPpVa4vCNxZvmORWTqNy1vpTMWzJM2BnrigDn9RmE85YdjiqTHANSyMCarSNk0ARStgfWq7HH0FSSNkmq8rdqAIycmkoooAKKKKACiiigD079mn/kuHhf/AK6Tf+iJK739s3P/AAsSz9BpFv8A+jrmuC/Zp/5Lh4X/AOuk3/oiSu+/bLGfiJa+2j2//o+5oA+c6VaAOaB1oAdRQaBnBoAKRqWkNADaWjFJQB3PhO7FxZvbyYLIO/pWoV8uUZP0PtXF+Hrz7JqVu2flY7Wrv7lCSpPIIOMUATwgbXVskkfLzT7ckRDcec9MUyEKV5OCOKswqApbYWwMDn9aALlpdIUC7iMAHHpXpmj3H2e2toyclmIAFeU2wVrxUIIOOn416JpsyyfZVzlo8E4oA6T40xGf4aWzjl43U9fQ141qjtLZ2lypPzRqWx6jivdPG8Yvfh1OuCdh3YxXgiyM2jQgjKo7IfbvQB1HgrMkxjcfu2Qg55ByK5LUbcWeq3EKkFA52/Q810Xg2Vo7tFyMb+vtVDx5D9m8UTxYxjB/TigDKU5OOlJglSe4NNPXIp0ZGcHrQA2JuMEYNMkU5J4xT2GAT2FNL7iQelAFO4XOPX1qpKuV9xWiQDkEVTkAyfSgDMuE3IeOaxLuLIJroZh8xz0rLuo+W460Ac5KuGqOrl1Hhj71ToAUU4dKZTloA/Sj4T/8ks8G/wDYGs//AEQlFHwn/wCSWeDf+wNZ/wDohKKAD4sf8ks8Zf8AYFvf/RD1+bUX+rk+n9a/SX4sf8ks8Zf9gW9/9EPX5tR/df6f1FAEVFFFAD4utaNpIYucZU1nRdavx/dFAGvDteL5ehrsPDmpg2EljIT5yD90f1xXE6UwFwYmPDdPrWyqtDeKVJBB60AdCZ33IWbkHGDXT6c6AxIo3buCPSuWjYXKAycOD2rqPD9sty6GXKIg3MR6CgDV1i7GnRqsDFZnHCrxjPeuPLbpiCCWbGc9qs6hfNe6gZ3H3jhR6DoKgucbywGCOhFAFshSECgZz19a0nhJiTHGWA4qtZqrWzc5fHAxWrZ/LHGX+YYxt/nQBmzQiQEk/wAR61CkKsChOXzUt7KqRkBcEc/Sq1o4SRG+8CQT70AX1toVjjORndkmtKRi03P3Quayp5t6pgDarVZkuP3JXHzsRjPYYoAg1cpKQq8s3U1mzwYJCHam39auXQMKgu2eM1kancsIG2vtB6mgDn9RZfPJ34UcCud1S9NzMFB+ROFFGr3xnuWVDhFrMZyTigCQvhcVXd8ZpzGoGPNADWb1qBjk5pztmmUAFFFFABRS0lABRRRQB6d+zT/yXDwv/wBdJv8A0RJXf/tjjd8SbYZ4GiQH/wAmJ64D9mn/AJLh4X/66Tf+iJK9A/bEGfibbe2gxHH/AG8zUAfOXejvQetKKAFooooAKKKKAEPTrTacelNoAmiPCkHkGvUdLnNzplvKOu38iK8ui6V6B4In8zT5YD1TJFAGsyjJUjnHGPapoZiYxt4296WdFCq68jHB/pSR7cFABgc0AETZlBzhuma7nwndBZgT1AyM/WuGjCmPbj5vX1rovDs5WaHGMg4OO9AHtLj7d4PvUYdEOefUV8+2cbPDqdrjlJBIB9Dg19BeG2W68NXy9DsII968ItwIfGdxabiPNVlOaAJ9ADRzMwH3SOab8TVP/CTRy9Vlt0OfcDFS2qmB5o0GXY4Bz0x/k07x5EbnS7O6x80blGx2B6UAcv2HTGKcoJAPeolOVxUuCoBoAGbIKnrUUgKnIFOLBjk8Uhb5TmgBhOTVWcEE1KzYk68U245waAKU65TPpWfdJkZrVcZU+hqjMAynFAHP3sWQTjmsqQYNdDcpyaxLpCrGgCtSgUlOBoA/Sj4T/wDJLPBv/YGs/wD0QlFHwn/5JZ4N/wCwNZ/+iEooAPix/wAks8Zf9gW9/wDRD1+bMXR/pX6TfFj/AJJZ4y/7At7/AOiHr82Yv4vpQBHRRRQBJF3rQjHAqhCK0YRz7UASplJAw4IrrHUTW8My9GUHPvXMIvOfaum0gedpOw9Ub8qAL2mONyqTz3rutOQf2dcSqwDFCo5654rhIIvk3DgqefpXbaVN5miy7B1XgD1oAzrazaTyVCZf1rUvdHj+wAgjzPl6d6t+HYPMSJSvzgkE9627m0j8+LB5XClW46UAcdHGVt5QCAQ23PcmtGzi22qso5Az+lMvrdre/MbkKp+Y4565q1Yruh3I2XwFoA57WpOSACDnDD0qvbIVwjBiDyCKs3o33cxcMeTgf1qOMyCbDghemc9KAJ43CWyrjcS/FXJcC4QhOwJrJgnWO52OeD93Fal1KDBwQG29qAMu7uTPOqIu5m4wOMVxnifUGa4a0hPypw59TXWQMIILy8kz+6Q7f96vN5XMjSSMclmzQBQm4c+pqMUs+S4pBQA2Vu1V3NSSHmoHPNADTSUUUAFFFFABRRRQAUUUUAenfs0/8lw8L/8AXSb/ANESV6D+2AM/FG39vD8R/wDJmWvPv2af+S4eF/8ArpN/6Ikr0P8Aa8wfipbAnk+Ho8f+BE1AHzeeppw6Uh6n1pRQAtJSmkoAKKKKAENNp5plAEsVdZ4MufI1AoTwwrk4etbGkS+TqEL++KAPTbmCQQbV+6CWGPTrVUjMQboSwGM1sxMJrC2kUcH5G/GsqRfnZSPlBP50AQtuiOO4OR9K09NkeIpICAC4P0rMdhuAbjNWbUhWVckhuKAPfPAFx51hdJ0+TPFeMeNkbS/H8U3T94D+BNeqfC+fdCFBPK469a4L4+WptvEdjKoA3xZ49QaAKmoyLBfT+UBywZc1bhtXv9G1GydSZDH5qZ9uRVa7xPZ6feBTiWIBsdz0rX0iXbeWrDONuDx26EfrQB5knfPUcGpMsU5/OrGsRC2129gQfKsrYHtmq79h+NAESgg7TUyxsRz2pdvc1IuevY0AVni6GomjzVyQZWq7j5cdDmgCpjhgR06VVlUDPrV6UbXBqrcLySBmgDKuUHNYd6vPtXRXCEjpWPfRnB4xQBiMMHFFPlGGqOgD9KvhP/ySzwb/ANgWy/8ARCUUfCf/AJJZ4N/7A1n/AOiEooAPix/ySzxl/wBgW9/9EPX5sx9/oa/Sb4sf8ks8Zf8AYFvf/RD1+bMX3j9KAGUlKetJQBPbjpWjACc1RthyK1IF+UmgCdE3H2ArpfDIBtruP2zWCi4UV0PhQf6TcJjOY84+lAFyLKRMAOTzzXQ+Hb3y45oHUeWwDAj2rA2lncjjHGBV7THESPNJ/qlHA9TQB6po1gkd/wDaYflt5U3Kfen6lamaRlf74cYJ9jS+D7lbzwxDLKD+4yF/OtLUQggE3ADHINAHH64EdlZRtKnn3FWNI2KjOcFDnp2pNXgE0sMaMA2Dn6f5xRYwNGiRBl2IAQfWgDB1SJlvJFA2sB1b61n38YVeDlz1PvXT+JoGW6BYAKyDJHWuVnOyQZ5QnINAFKSMriQAKyDkVcnJ+xo3OSCT9KYkYcyl/ukipoQDbuhOQpx+FAGT4m/ceFdsfDTSD8q89uV8pimenWvSfFaBtKtY19d2BXm+okfanxQBnTdc1EGyDUtx0qtnigBjng1CeTT5D2qOgAooooAKKKKACiiigAooooA9O/Zp/wCS4eF/+uk3/oiSvQ/2u8f8Lass9/D6/wDo6evPP2af+S4eF/8ArpN/6Ikr0L9rsj/hbmnA550Bf/RtxQB84t9406kbhj9aKAFpDS0hoAKKKKAA02nU2gCWDrV2IlXRh2Oaowfeq+o+XNAHsHhOT7VphhONxwVPvUGowlZ9zYXPUe9UPh7clkjB5xiun8RWbpMxCjDfOKAOXdfmyT0NWdNbLmJucDj2ps0LJKQxADc022TE6MG6mgD2H4UyliqDGdpXn+9zWH+0DF5kOk3WP4njP6GtH4at9nvXUHKnlTVz47WIbwTFOV+eG6Vs+gIIoA4DQZPtXg6Nc/NBIV68gdq1bRjFPCN+SXIwPQiud8Dz50rULf8AiBDrx3rZtpPLKygk42tjHvigDE8d2wtPERlAO2dFfp3xg1hbDI2SOK7n4nQ+ZaaZeKOGBUnFcXC2AMUAOMZC/N0NPiQFMZ5oL560oIU8UAIYxjjmq1ygBGBVo8jIODmopcMuD1oArMOOgNVZQOKtOOBzmoLjoTQBm3C5bnoRWRerndW3N933rKu170Ac3crgke9V60L1DuJxVCgD9KfhP/ySzwb/ANgWy/8ARCUUfCf/AJJZ4N/7A1n/AOiEooAPix/ySzxl/wBgW9/9EPX5sw/f/Cv0r+JttPefDbxZa2cMs9zPpN3HFFEhZ5HaFwFUDkkkgACvz+i+HPjcN/yJ3iT/AMFc/wD8TQByR60DrXVH4ceN8/8AIm+JP/BXP/8AE0q/DjxvkZ8G+JP/AAVz/wDxNAGDaLk1rQJkAHpWzafDzxoqjd4Q8RD66ZN/8TWtD4A8XjGfCniAf9w6b/4mgDnY1rf8HDGtoOPmRh+lXk8BeLe/hbXgP+wfN/8AE1t+D/A/ieHxFaPceGtbih3Hcz2EqgDB6krQBkbfll28EucmrDQr9hkb5iqrnPpXQjwV4j+1yr/wj2sbC2QfsUmP/Qa0Lvwd4hXwvdrHoGqmZiqiNbOTceeuNtAGl8O7xrjw89uiqXTsf5107RtPZ7HxvVTgdqwPhf4Z16zvJVvdF1OBGTrLaSIPzIrv10PUIw22wuz83/PFjn9KAPPLmNzdqVA2px7nnFWrWzCK445YNwOmQK6W50DUvMBTSr3JPIFu+B+lRjQ9WXep0q/5OSRbvz+lAHJeKWVrlQMqwXaQOea5W8s8Q8g7ee1d1qfhnW5Z0b+x9SZmHJW1f/CoLjwvrcsEg/sXUw3GP9Fk/wAKAPP7VXkmKYGKfeRNFGvO1iQK6m38I69FON2haqVIwT9jk4P/AHzUl34R16WSFBoeqlSwJP2STj9KAPP/ABhH5V1FGXOEjBrzm8Ae4dhyM165418IeKrnVJjB4a1uVAAoZLCVgcDsQtcVJ8P/ABlyR4S8QHJz/wAg2b/4mgDi7hAVqoy4rt5fh94zKEf8Ij4i/wDBZN/8TVI/DvxsT/yJ3iP/AMFc/wD8TQBxr/eptdY3w58blj/xRviT/wAFc/8A8TSf8K48cf8AQm+JP/BXP/8AE0AcpRXV/wDCuPHH/Qm+JP8AwVz/APxNH/CuPHH/AEJviT/wVz//ABNAHKUV1f8Awrjxx/0JviT/AMFc/wD8TR/wrjxx/wBCb4k/8Fc//wATQBylFdX/AMK48cf9Cb4k/wDBXP8A/E0f8K48cf8AQm+JP/BXP/8AE0AcpRXV/wDCuPHH/Qm+JP8AwVz/APxNH/CuPHH/AEJviT/wVz//ABNAHR/s0/8AJcPC/wD10m/9ESV6D+12cfGDS+OugqP/ACLcVz/7PfgjxXpXxi8OXuqeGNcsrOKSUyT3FhLHGmYXAyzKAOSB+Ndx+1J4X8Q6z8VtMu9G0HVdQtU0dImmtbOSVFfzZ/lLKCAcMDj3FAHy2/3zRXVv8OfG+4keDvEn/grn/wDiaT/hXPjf/oTvEn/grn/+JoA5akNdX/wrnxv/ANCb4k/8Fc//AMTSH4c+N/8AoTfEn/grn/8AiaAOVpwXIzmuo/4Vz43/AOhN8Sf+Cuf/AOJp6fDrxvjnwd4k/wDBXP8A/E0AcmRimEV1zfDnxv8A9Cd4k/8ABXP/APE0w/Dnxx/0JviT/wAFc/8A8TQBy8J+atSEjYK1Y/hz43Dc+DfEn/grn/8Aiavx/D7xrtA/4RDxGB/2DJ//AImgCx4EuvLmKZ5DV69q0DXWiQ3UfLxYz7ivL/D/AIF8Z21+C/hTxAinudOmA/8AQa9x0Hw5rcmlSQXOjaihZfuyWsi/zFAHlmrAbUYd+tU0AVkGCK63UfBniMK6poGruQ2BtspDkf8AfNZ//CG+KNwY+HNa4/6cZf8A4mgDq/h65N4hH9zBya7X4q2/234a6iF+YoA479DXI+BdA1+1vYzc6Fq0S9MvZyKP1Fen+ItGvrzwLfWsdncmd42AjETFjx0xjNAHzL4EctfTwg482I4+o5ro1MhLru4AO0fjWf4Z8H+KrLV7WWTw1rioHwxNhKBj/vmusm8I66bs40LVsI7bSLSTBH5UAR+IY21LwPIpyXtGDqfY9a80jPygd69u0bwzrMthc2lzpGoxpLEy/PauOo47V5iPBPilXKnw1rXBK5FjLg+/3aAMcrlRig8KMjkVvJ4N8UAEf8I3rX/gBL/8TSf8IZ4oKn/im9bz/wBeEv8A8TQBixEYxTJUByRkGttfBnilAP8Aim9bJ/68Jf8A4mpj4N8TsvPhvWgf+vGX/wCJoA5faMd6gliZk+Ugg108ngrxT1Xw1rf/AIAS/wDxNRt4M8VYOPDOudP+fCX/AOJoA4+SPKEn0rNuVBXNdq/gjxaVOPC+u9P+gfN/8TWfN4E8X+WQPCmvnPpp03/xNAHB3y5Q1iHqa9Eufh/4zMeF8I+IT/3DZv8A4mseT4c+Ny5x4N8SY/7Bc/8A8TQB9+/Cf/klng3/ALAtl/6ISipfhlbT2fw28KWt3DLBcw6TaRyxSqVeN1hQFWB5BBBBBooA6WiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These anteroposterior and lateral views of the knee demonstrate multiple calcified intraarticular loose bodies (arrows) consistent with synovial osteochondromatosis. Also noted is severe medial and lateral joint space narrowing and osteophyte formation consistent with concomitant osteoarthritis of the knee joint.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahla Modarresi, MD and Celia M Jude, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_0_2051=[""].join("\n");
var outline_f2_0_2051=null;
var title_f2_0_2052="Oxymetazoline (ophthalmic): Patient drug information";
var content_f2_0_2052=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Oxymetazoline (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/46/9955?source=see_link\">",
"     see \"Oxymetazoline (ophthalmic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/40/32386?source=see_link\">",
"     see \"Oxymetazoline (ophthalmic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9504322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Visine&reg; L.R.&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691838",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702660",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to oxymetazoline or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is used on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12277 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-9F69235DB9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_0_2052=[""].join("\n");
var outline_f2_0_2052=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504322\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024429\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024428\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024433\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024434\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024436\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024431\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024432\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024437\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024438\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/14/13541?source=related_link\">",
"      Oxymetazoline (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/25/23956?source=related_link\">",
"      Oxymetazoline (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/52/22340?source=related_link\">",
"      Oxymetazoline (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/46/9955?source=related_link\">",
"      Oxymetazoline (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/40/32386?source=related_link\">",
"      Oxymetazoline (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_0_2053="Fiberglass fx tape";
var content_f2_0_2053=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Fiberglass casting tape",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fiberglass casting tape is lighter, stronger, more breathable, and sets more quickly than plaster. It should be applied with a stretch-relax technique.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Titus, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_0_2053=[""].join("\n");
var outline_f2_0_2053=null;
var title_f2_0_2054="Acute varicella pneumonia PA";
var content_f2_0_2054=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute varicella pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph reveals multiple so-called acinar nodules, 5-10 mm in diameter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_0_2054=[""].join("\n");
var outline_f2_0_2054=null;
var title_f2_0_2055="Suppurative (septic) thrombophlebitis";
var content_f2_0_2055=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Suppurative (septic) thrombophlebitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/0/2055/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/0/2055/contributors\">",
"     Denis Spelman, MBBS, FRACP, FRCPA, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/0/2055/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/0/2055/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/0/2055/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/0/2055/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/0/2055/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suppurative thrombophlebitis refers to venous thrombosis associated with inflammation in the setting of bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/1\">",
"     1",
"    </a>",
"    ]. Histologic findings consist of inflammation and suppuration within the vein wall. Thrombus with or without pus may be seen within the vein lumen, with evidence of perivascular inflammation.",
"   </p>",
"   <p>",
"    Suppurative thrombophlebitis should be suspected in patients with persistent bacteremia after 72 hours of appropriate antimicrobial therapy, particularly in the setting of an intravascular catheter. The diagnosis may be made based on culture data together with radiographic evidence of thrombosis. The principles of treatment for suppurative thrombophlebitis include removing the focus of infection (eg, intravenous catheter), prompt administration of intravenous antibiotics, and consideration regarding surgical intervention",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anticoagulation.",
"   </p>",
"   <p>",
"    The pathogenesis, clinical manifestations, microbiology, diagnosis, and treatment of suppurative thrombophlebitis of peripheral and jugular veins and the superior and inferior vena cava will be reviewed here. Issues related to portal vein pylephlebitis, septic dural thrombosis, and septic pelvic thrombophlebitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33254?source=see_link\">",
"     \"Pylephlebitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23145?source=see_link\">",
"     \"Septic dural sinus thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6807?source=see_link\">",
"     \"Septic pelvic thrombophlebitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PERIPHERAL VEIN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral vein suppurative thrombophlebitis occurs most frequently in the setting of an intravenous catheter or peripherally inserted central venous catheter (PICC) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/2\">",
"     2",
"    </a>",
"    ]. Most cases of intravenous catheter sepsis are not complicated by suppurative thrombophlebitis; in one series including 102 episodes, suppurative thrombophlebitis was observed in 7 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of peripheral vein suppurative thrombophlebitis is highest in patients with specific risk factors such as burns [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/4\">",
"     4",
"    </a>",
"    ], steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/5\">",
"     5",
"    </a>",
"    ], and injection drug use [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/6\">",
"     6",
"    </a>",
"    ]. Burn patients may be at particular risk due to several factors including high skin inoculum of organisms, hyperalimentation, use of broad spectrum antibiotics, and impairment of local defense due to loss of skin integrity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral vein suppurative thrombophlebitis should be suspected in patients with persistent bacteremia after 72 hours of appropriate antimicrobial therapy, particularly in the setting of an intravascular catheter. Accompanying clinical manifestations include fever, erythema, tenderness, and purulent drainage at the site of the involved vessel [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Complications of peripheral vein suppurative thrombophlebitis include septic pulmonary emboli and secondary pneumonia; these may also be presenting manifestations of the infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Microbiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of peripheral vein suppurative thrombophlebitis is Staphylococcus aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]; streptococci and Enterobacteriaceae are also well-described pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. Nosocomial pathogens may have antimicrobial resistance. Burn patients may have polymicrobial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/7\">",
"     7",
"    </a>",
"    ]. Fungi are less common in peripheral vein suppurative thrombophlebitis than in",
"    <span class=\"nowrap\">",
"     superior/inferior",
"    </span>",
"    vena cava infection but may be increasing in incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The microbiologic diagnosis may be made based on culture of blood, purulent material expressed from the site, aspirate from the vein, or direct culture of the vein itself [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. These findings may be used in conjunction with ultrasound for diagnosis of peripheral vein septic thrombophlebitis. An ultrasound may not be needed, but a baseline ultrasound may be useful if subsequent repeat evaluation is needed to evaluate for extension of thrombus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles of treatment include removing the focus of infection (eg, intravenous catheter), prompt administration of intravenous antibiotics, and consideration regarding surgical intervention",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anticoagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric therapy for peripheral vein suppurative thrombophlebitis should include an agent with activity against staphylococci such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in two equally divided doses, not to exceed 2 g per day unless serum concentrations are inappropriately low) plus an agent with activity against Enterobacteriaceae such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (1 g IV daily). Antibiotics should be tailored accordingly to culture and sensitivity data when available.",
"   </p>",
"   <p>",
"    The optimal duration of antibiotic therapy is unknown; a minimum of 2 weeks intravenous therapy is appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/10\">",
"     10",
"    </a>",
"    ]. The duration may be abbreviated in some situations; among 36 injection drug users with suppurative thrombophlebitis, no relapses occurred when treatment was given for &gt;7 days intravenously and followed by oral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, most favor surgical intervention in the setting of sepsis or for patients who have not responded appropriately to antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. When surgical intervention is warranted, incision and drainage and, potentially, excision of the affected vein and its tributaries may be needed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/8,12,13\">",
"     8,12,13",
"    </a>",
"    ]. Incision and drainage alone may be inadequate treatment since it does not remove the septic focus and recurrent bacteremia can occur; in such cases, radical vein excision may be warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/8,14\">",
"     8,14",
"    </a>",
"    ]. In one series of 24 cases in burn patients, 7 of 10 treated surgically survived; for 13 of the remaining 14, the diagnosis was only made at autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the benefit of anticoagulation for management of peripheral vein thrombophlebitis is uncertain. Some authors favor anticoagulation only if there is evidence for extension of thrombus; there are no controlled studies. We suggest not administering anticoagulation in the absence of evidence for extension of thrombus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     JUGULAR VEIN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jugular vein suppurative thrombophlebitis is also known as Lemierre's syndrome, postanginal sepsis, and necrobacillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/15\">",
"     15",
"    </a>",
"    ]. The condition is frequently preceded by pharyngitis, usually in association with tonsil or peritonsillar involvement. Other antecedent conditions include primary dental infection or infectious mononucleosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Jugular vein suppurative thrombophlebitis is characterized by infectious involvement of the carotid sheath vessels with bacteremia. In general, infection progresses from the oropharynx to the parapharyngeal or lateral pharyngeal space. The anterior part of this space consists of the anterior neck muscles; the posterior section contains the carotid sheath that encloses the internal jugular vein, internal carotid artery, the vagal nerve, and lymph nodes (",
"    <a class=\"graphic graphic_figure graphicRef67251 \" href=\"UTD.htm?7/39/7797\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Jugular vein suppurative thrombophlebitis can also be associated with intravenous catheter insertion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jugular vein suppurative thrombophlebitis should be suspected in patients with antecedent pharyngitis, septic pulmonary emboli, and persistent fever despite antimicrobial therapy.",
"   </p>",
"   <p>",
"    Jugular vein suppurative thrombophlebitis frequently affects previously healthy young adults; in one series the mean age was 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/6\">",
"     6",
"    </a>",
"    ]. The interval between the preceding pharyngitis and the onset of jugular vein thrombophlebitis is usually less than one week [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/9,16\">",
"     9,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients typically present acutely with fever (&gt;39&ordm;C) and rigors, often accompanied by respiratory distress [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/9\">",
"     9",
"    </a>",
"    ]. Most patients have localized neck",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    throat pain. Clinical examination of the oropharynx may demonstrate ulceration, a pseudomembrane, or erythema [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/9,16\">",
"     9,16",
"    </a>",
"    ]. Tenderness, swelling,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    induration may be observed overlying the jugular vein, over the angle of the jaw or along the sternocleidomastoid muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/17\">",
"     17",
"    </a>",
"    ]. In some cases there are no abnormal physical findings in the oropharynx.",
"   </p>",
"   <p>",
"    Septic emboli to the lung are common; in two reports this finding was observed in 97 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/9,16\">",
"     9,16",
"    </a>",
"    ]. Chest radiography may demonstrate infiltrates, which can cavitate to form lung abscesses and empyema [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/17\">",
"     17",
"    </a>",
"    ]. Metastatic infection can also occur at other sites, leading to empyema, septic arthritis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/4,9\">",
"     4,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Microbiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causative organisms of jugular vein suppurative thrombophlebitis are usually members of the normal oropharyngeal flora [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/16\">",
"     16",
"    </a>",
"    ]. The most common pathogen is the anaerobe Fusobacterium necrophorum; this pathogen has been isolated in healthy individuals as well as those with jugular vein suppurative thrombophlebitis and tonsillitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/18\">",
"     18",
"    </a>",
"    ]. Other pathogens include other Fusobacterium species (eg, F. nucleatum) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/16\">",
"     16",
"    </a>",
"    ] and other organisms such as Eikenella corrodens [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/19\">",
"     19",
"    </a>",
"    ], Porphyromonas asaccharolytica [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/20\">",
"     20",
"    </a>",
"    ], streptococci including S. pyogenes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/21\">",
"     21",
"    </a>",
"    ], and Bacteroides [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/9\">",
"     9",
"    </a>",
"    ]. Organisms may be isolated from the blood and from metastatic sites of infection.",
"   </p>",
"   <p>",
"    Catheter associated jugular vein suppurative thrombophlebitis is associated with skin flora and nosocomial pathogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jugular vein suppurative thrombophlebitis should be suspected in patients with antecedent pharyngitis, septic pulmonary emboli, and persistent fever despite antimicrobial therapy.",
"   </p>",
"   <p>",
"    The microbiologic diagnosis may be made based on culture of blood, and culture purulent material expressed from the site if present.",
"   </p>",
"   <p>",
"    The most useful radiographic tool to evaluate for jugular vein suppurative thrombophlebitis is high resolution computed tomography (CT) scan with contrast. It may demonstrate filling defects or thrombus, with or without soft tissue swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/16\">",
"     16",
"    </a>",
"    ]. Ultrasonography may be used to evaluate for jugular vein thrombosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    assess for extension of thrombus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/16\">",
"     16",
"    </a>",
"    ]. This imaging is less useful in regions deep to the clavicle or mandible. There is limited experience with magnetic resonance (MR) imaging, but it has been suggested to be a useful modality [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles of treatment include removing the focus of infection (eg, intravenous catheter), prompt administration of intravenous antibiotics, and consideration regarding surgical intervention",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anticoagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric therapy for jugular vein suppurative thrombophlebitis should include a beta-lactamase resistant beta-lactam antibiotic, since treatment failure with penicillin and F. necrophorum beta-lactamase production has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/16,23\">",
"     16,23",
"    </a>",
"    ]. Acceptable regimens include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    (3 g every six hours),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    (4.5 g every six hours),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/45/42710?source=see_link\">",
"     ticarcillin-clavulanate",
"    </a>",
"    (3.1 g every six hours), or monotherapy with a carbapenem. Antibiotics should be tailored accordingly to culture and susceptibility data when available.",
"   </p>",
"   <p>",
"    In the setting of catheter associated jugular vein suppurative thrombophlebitis, empiric therapy should also include an agent with activity against skin flora such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in two equally divided doses, not to exceed 2 g per day unless serum concentrations are inappropriately low).",
"   </p>",
"   <p>",
"    The duration of therapy generally is for at least four weeks, including a minimum of 2 weeks intravenous therapy followed by oral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/24\">",
"     24",
"    </a>",
"    ], or until pulmonary abscesses have resolved as demonstrated by CT scan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, most favor surgical intervention only in the setting of ongoing sepsis or for patients who have not responded to antimicrobial therapy; there are no randomized trials to guide such decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. When surgical intervention is warranted, surgical ligation or excision of the internal jugular vein may be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/6,9\">",
"     6,9",
"    </a>",
"    ]. Surgical drainage of pulmonary abscesses or empyema may also be warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adjacent peritonsillar or other neck abscess in the vicinity of a catheter should prompt surgical incision and drainage as well as catheter removal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of anticoagulation for jugular vein suppurative thrombophlebitis is controversial; there are no controlled studies. Some authors favor anticoagulation only if there is evidence for extension of thrombus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/16\">",
"     16",
"    </a>",
"    ]. We suggest not administering anticoagulation in the absence of evidence for extension of thrombus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     VENA CAVA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suppurative thrombophlebitis of the superior vena cava (SVC) and inferior vena cava (IVC) occurs most frequently in the setting of a central venous catheter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vena cava suppurative thrombophlebitis should be suspected in patients with persistent bacteremia after 72 hours of appropriate antimicrobial therapy, particularly in the setting of an intravascular catheter.",
"   </p>",
"   <p>",
"    In both inferior and superior vena cava suppurative thrombophlebitis, patients typically present with systemic symptoms (fever, rigors and hypotension). Localized findings are not common but may include with evidence of occlusion with edema distal to the involved vein [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of vena cava suppurative thrombophlebitis may be made based on culture data together with radiographic evidence of thrombosis.",
"   </p>",
"   <p>",
"    The microbiologic diagnosis may be made based on blood cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. Patients with suppurative thrombophlebitis of the great veins frequently have prolonged positive blood cultures even in the setting of appropriate therapy.",
"   </p>",
"   <p>",
"    The most useful radiographic tool to evaluate for vena cava suppurative thrombophlebitis is high resolution computed tomography (CT) scan [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/14\">",
"     14",
"    </a>",
"    ]. It may demonstrate filling defects or thrombus, with or without soft tissue swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/16\">",
"     16",
"    </a>",
"    ]. Ultrasound may be used to confirm central vein thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/5\">",
"     5",
"    </a>",
"    ]. Indium white cell scans may not be reliable for the diagnosis of vena cava thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Microbiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of vena cava suppurative thrombophlebitis are nosocomial organisms including Staphylococcus aureus and Enterobacteriaceae [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fungi are more common in",
"    <span class=\"nowrap\">",
"     superior/inferior",
"    </span>",
"    vena cava infection than in peripheral vein suppurative thrombophlebitis. In one report of eight patients with Candida septic thrombosis of the great central veins, all had a central venous catheter for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (TPN) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/5\">",
"     5",
"    </a>",
"    ]. Involvement of the SVC, IVC and subclavian veins was observed in four, one, and four cases, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles of treatment include removing the focus of infection (eg, intravenous catheter), prompt administration of intravenous antibiotics, and consideration regarding surgical intervention",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anticoagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric therapy for vena cava suppurative thrombophlebitis should include an agent with activity against staphylococci such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in two equally divided doses, not to exceed 2 g per day unless serum concentrations are inappropriately low) plus an agent with activity against Enterobacteriaceae such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (1 g IV daily). The optimal duration of antibiotic therapy is uncertain; intravenous antimicrobial therapy for up to 4 to 6 weeks is appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/2\">",
"     2",
"    </a>",
"    ]. Antibiotics should be tailored accordingly to culture and susceptibility data when available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical excision or ligation is not possible for vena cava suppurative thrombophlebitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/12\">",
"     12",
"    </a>",
"    ]. Resection of the infected thrombus may be warranted if proximal thrombus propagation occurs despite antibiotic and anticoagulation therapy. Transabdominal and transfemoral venous thrombectomy has been performed for infected IVC thrombus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most favor anticoagulation in the setting of vena cava suppurative thrombophlebitis, although there are no controlled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2055/abstract/5,14\">",
"     5,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suppurative thrombophlebitis refers to venous thrombosis associated with inflammation in the setting of bacteremia. It should be suspected in patients with persistent bacteremia after 72 hours of appropriate antimicrobial therapy, particularly in the setting of an intravascular catheter. Accompanying clinical manifestations may include fever, erythema, tenderness and purulent drainage at the site of the involved vessel. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of suppurative thrombophlebitis is made based on clinical manifestations, culture data and radiographic evidence of thrombosis. The principles of treatment for suppurative thrombophlebitis include removing the focus of infection (eg, intravenous catheter), prompt administration of intravenous antibiotics, and consideration regarding surgical intervention",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anticoagulation. Once culture data are available, antibiotic therapy should be tailored to the organisms detected. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common cause of peripheral vein suppurative thrombophlebitis is Staphylococcus aureus; streptococci and Enterobacteriaceae are also well-described pathogens. We suggest empiric antibiotic therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      plus a cephalosporin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The duration of therapy should be at least 2 weeks. In general, most favor surgical intervention only in the setting of ongoing sepsis or for patients who have not responded to antimicrobial therapy. We suggest NOT administering anticoagulation in the absence of evidence for extension of thrombus (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Peripheral vein'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The causative organisms of jugular vein suppurative thrombophlebitis are usually members of the normal oropharyngeal flora; the most common is Fusobacterium necrophorum. We suggest empiric antibiotic therapy with a beta-lactamase resistant beta-lactam antibiotic (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The duration of therapy should be at least 4 weeks. In general, most favor surgical intervention only in the setting of ongoing sepsis or for patients who have not responded to antimicrobial therapy. We suggest NOT administering anticoagulation in the absence of evidence for extension of thrombus (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Jugular vein'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common causes of vena cava suppurative thrombophlebitis are nosocomial organisms including Staphylococcus aureus and Enterobacteriaceae. We suggest empiric antibiotic therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      plus a cephalosporin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The duration of therapy should be at least 4 weeks. Surgical ligation is not possible for vena cava suppurative thrombophlebitis, although resection of the infected thrombus may be warranted if proximal thrombus propagation occurs despite antibiotic and anticoagulation therapy. We suggest administering anticoagulation in the setting of vena cava suppurative thrombophlebitis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Vena cava'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2055/abstract/1\">",
"      Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2055/abstract/2\">",
"      Andes DR, Urban AW, Acher CW, Maki DG. Septic thrombosis of the basilic, axillary, and subclavian veins caused by a peripherally inserted central venous catheter. Am J Med 1998; 105:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2055/abstract/3\">",
"      Arnow PM, Quimosing EM, Beach M. Consequences of intravascular catheter sepsis. Clin Infect Dis 1993; 16:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2055/abstract/4\">",
"      Pruitt BA Jr, McManus WF, Kim SH, Treat RC. Diagnosis and treatment of cannula-related intravenous sepsis in burn patients. Ann Surg 1980; 191:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2055/abstract/5\">",
"      Strinden WD, Helgerson RB, Maki DG. Candida septic thrombosis of the great central veins associated with central catheters. Clinical features and management. Ann Surg 1985; 202:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2055/abstract/6\">",
"      Baker CC, Petersen SR, Sheldon GF. Septic phlebitis: a neglected disease. Am J Surg 1979; 138:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2055/abstract/7\">",
"      O'Neill JA Jr, Pruitt BA Jr, Foley FD, Moncrief JA. Suppurative thrombophlebitis--a lethal complication of intravenous therapy. J Trauma 1968; 8:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2055/abstract/8\">",
"      Khan EA, Correa AG, Baker CJ. Suppurative thrombophlebitis in children: a ten-year experience. Pediatr Infect Dis J 1997; 16:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2055/abstract/9\">",
"      Sinave CP, Hardy GJ, Fardy PW. The Lemierre syndrome: suppurative thrombophlebitis of the internal jugular vein secondary to oropharyngeal infection. Medicine (Baltimore) 1989; 68:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2055/abstract/10\">",
"      Gillespie P, Siddiqui H, Clarke J. Cannula related suppurative thrombophlebitis in the burned patient. Burns 2000; 26:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2055/abstract/11\">",
"      Mertz D, Khanlari B, Viktorin N, et al. Less than 28 days of intravenous antibiotic treatment is sufficient for suppurative thrombophlebitis in injection drug users. Clin Infect Dis 2008; 46:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2055/abstract/12\">",
"      Villani C, Johnson DH, Cunha BA. Bilateral suppurative thrombophlebitis due to Staphylococcus aureus. Heart Lung 1995; 24:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2055/abstract/13\">",
"      Stein JM, Pruitt BA Jr. Suppurative thrombophlebitis. A lethal iatrogenic disease. N Engl J Med 1970; 282:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2055/abstract/14\">",
"      Kniemeyer HW, Grabitz K, Buhl R, et al. Surgical treatment of septic deep venous thrombosis. Surgery 1995; 118:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2055/abstract/15\">",
"      Riordan T, Wilson M. Lemierre's syndrome: more than a historical curiosa. Postgrad Med J 2004; 80:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2055/abstract/16\">",
"      Golpe R, Mar&iacute;n B, Alonso M. Lemierre's syndrome (necrobacillosis). Postgrad Med J 1999; 75:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2055/abstract/17\">",
"      Chirinos JA, Lichtstein DM, Garcia J, Tamariz LJ. The evolution of Lemierre syndrome: report of 2 cases and review of the literature. Medicine (Baltimore) 2002; 81:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2055/abstract/18\">",
"      Jensen A, Hagelskjaer Kristensen L, Prag J. Detection of Fusobacterium necrophorum subsp. funduliforme in tonsillitis in young adults by real-time PCR. Clin Microbiol Infect 2007; 13:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2055/abstract/19\">",
"      Celikel TH, Muthuswamy PP. Septic pulmonary emboli secondary to internal jugular vein phlebitis (postanginal sepsis) caused by Eikenella corrodens. Am Rev Respir Dis 1984; 130:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2055/abstract/20\">",
"      Morizono S, Enjoji M, Sonoda N, et al. Lemierre's syndrome: Porphyromonas asaccharolytica as a putative pathogen. Intern Med 2005; 44:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2055/abstract/21\">",
"      Anton E. Lemierre syndrome caused by Streptococcus pyogenes in an elderly man. Lancet Infect Dis 2007; 7:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2055/abstract/22\">",
"      Auber AE, Mancuso PA. Lemierre syndrome: magnetic resonance imaging and computed tomographic appearance. Mil Med 2000; 165:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2055/abstract/23\">",
"      Seidenfeld SM, Sutker WL, Luby JP. Fusobacterium necrophorum septicemia following oropharyngeal infection. JAMA 1982; 248:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2055/abstract/24\">",
"      Hagelskjaer Kristensen L, Prag J. Lemierre's syndrome and other disseminated Fusobacterium necrophorum infections in Denmark: a prospective epidemiological and clinical survey. Eur J Clin Microbiol Infect Dis 2008; 27:779.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2131 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-1201EFFE29-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_0_2055=[""].join("\n");
var outline_f2_0_2055=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PERIPHERAL VEIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Microbiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      JUGULAR VEIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Microbiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      VENA CAVA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Microbiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2131\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2131|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/39/7797\" title=\"figure 1\">",
"      Anatomy of the parapharyngeal space",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33254?source=related_link\">",
"      Pylephlebitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23145?source=related_link\">",
"      Septic dural sinus thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6807?source=related_link\">",
"      Septic pelvic thrombophlebitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_0_2056="Terminal villi";
var content_f2_0_2056=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Term placenta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal term placenta showing a spectrum of villous sizes with terminal villi predominating.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla J Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_0_2056=[""].join("\n");
var outline_f2_0_2056=null;
var title_f2_0_2057="Nefazodone: Drug information";
var content_f2_0_2057=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nefazodone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/61/42965?source=see_link\">",
"    see \"Nefazodone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/7/1145?source=see_link\">",
"    see \"Nefazodone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F200339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Serotonin Reuptake Inhibitor/Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F200312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Depression:",
"     </b>",
"     Oral: 200 mg/day, administered in two divided doses initially, with a range of 300-600 mg/day in 2 divided doses thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Post-traumatic stress disorder (PTSD) (unlabeled use):",
"     </b>",
"     Oral: Initial: 100 mg twice daily; target dose: 600 mg/day (average daily dose: 463 mg).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F200313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Initial: 50 mg twice daily; increase dose to 100 mg twice daily in 2 weeks; usual maintenance dose: 200-400 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F200284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 50 mg, 100 mg, 150 mg, 200 mg, 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F200268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=4522\" target=\"_blank\">",
"      file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=4522",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F200289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosing after meals may decrease lightheadedness and postural hypotension, but may also decrease absorption and therefore effectiveness.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F200288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of depression",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F200335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Post-traumatic stress disorder (PTSD)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F200348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Serzone&reg; may be confused with selegiline, SEROquel&reg;, sertraline",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F200337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache, drowsiness, insomnia, agitation, dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia, nausea, constipation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, hypotension, orthostatic hypotension, peripheral edema, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills, fever, incoordination, lightheadedness, confusion, memory impairment, abnormal dreams, decreased concentration, ataxia, psychomotor retardation, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain, impotence, libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Gastroenteritis, vomiting, dyspepsia, diarrhea, increased appetite, thirst, taste perversion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary frequency, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hematocrit decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, hypertonia, paresthesia, neck rigidity, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (9%), abnormal vision (7%), eye pain, visual field defect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis, cough, dyspnea, pharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu syndrome, infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reaction, angioedema, AV block, galactorrhea, gynecomastia, hallucinations, hepatic failure, hepatic necrosis, hepatitis, hyponatremia, impotence, increased prolactin, leukopenia, liver function tests (abnormal), photosensitivity, priapism, rhabdomyolysis (with lovastatin/simvastatin), seizure, serotonin syndrome, Stevens-Johnson syndrome, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F200292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nefazodone, related compounds (phenylpiperazines), or any component of the formulation; liver injury due to previous nefazodone treatment, active liver disease, or elevated serum transaminases; concurrent use or use of MAO inhibitors within previous 14 days; use in a patient during the acute recovery phase of MI; concurrent use with carbamazepine, cisapride, or pimozide; concurrent therapy with triazolam or alprazolam is generally contraindicated (dosage must be reduced by 75% for triazolam and 50% for alprazolam; such reductions may not be possible with available dosage forms).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F200272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      Nefazodone is not FDA approved for use in children.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. The degree of anticholinergic blockade produced by this agent is very low relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic failure: Cases of life-threatening hepatic failure have been reported (risk should be considered when choosing an agent for the treatment of depression); discontinue if clinical signs or symptoms suggest liver failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension (risk is low relative to other antidepressants); use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May cause sedation, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). The degree of sedation is low relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sexual dysfunction: Rare reports of priapism have occurred. The incidence of sexual dysfunction with nefazodone is generally lower than with SSRIs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with a history of cardiovascular disease (including previous MI, stroke, tachycardia, or conduction abnormalities); the risk conduction abnormalities with this agent is very low relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Nefazodone is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs; does not potentiate ethanol but use is not advised.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Therapy should not be abruptly discontinued in patients receiving high doses for prolonged periods.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F200333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2B6 (weak), CYP2C8 (weak), CYP2D6 (weak), CYP3A4 (strong);",
"     <b>",
"      Induces",
"     </b>",
"     P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F200277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). Specifically, this may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. Antidepressants (Serotonin Reuptake Inhibitor/Antagonist) may enhance the hypotensive effect of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the serotonergic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Nefazodone. Concentrations of active Nefazodone metabolites may also be reduced. Nefazodone may increase the serum concentration of CarBAMazepine. Also, concentrations of the active CarBAMazepine epoxide metabolite may be reduced.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Nefazodone may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Nefazodone may increase the serum concentration of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Nefazodone may decrease the metabolism of CloZAPine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible.  Closely monitor for decreased levels/effects of dabigatran if concomitantly administering  p-glycoprotein inducers, particularly strong inducers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Nefazodone may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Nefazodone may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Nefazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the serotonergic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Antidepressants (Serotonin Reuptake Inhibitor/Antagonist) may decrease the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Antidepressants (Serotonin Reuptake Inhibitor/Antagonist) may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.  Management: Recommendations regarding concomitant use of vardenafil with strong CYP3A4 inhibitors may vary depending on brand name (e.g., Levitra, Staxyn) or by international labeling. Consult appropriate product labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F200305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Nefazodone absorption may be delayed and bioavailability may be decreased if taken with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, SAMe, kava kava (may increase risk of serotonin syndrome and/or excessive sedation).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F200279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5722223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were observed in some animal reproduction studies. When nefazodone is taken during pregnancy, an increased risk of major malformations has not been observed in the limited number of pregnancies studied (Einarson, 2003; Einarson, 2009). The long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     exposure to nefazodone on infant development and behavior are not known.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The ACOG recommends that therapy with antidepressants during pregnancy be individualized; treatment of depression during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. Consideration should be given to using agents with safety data in pregnancy. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy (ACOG, 2008; APA, 2010; Yonkers, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F200317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F200296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nefazodone and its metabolites are excreted in breast milk. Drowsiness, lethargy, poor feeding, and failure to maintain body temperature have been reported in a premature nursing infant. Adverse events were not observed in two case reports of older infants (Dodd, 2000; Yapp, 2000). The long-term effects on neurobehavior have not been studied. The manufacturer recommends that caution be exercised when administering nefazodone to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F200295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Nefazodone HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $197.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (60): $121.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (60): $123.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (60): $125.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (60): $128.18",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F200281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If AST/ALT increase &gt;3 times ULN, the drug should be discontinued and not reintroduced; mental status for depression, suicide ideation (especially at the beginning of therapy or when doses are increased or decreased), anxiety, social functioning, mania, panic attacks",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F200285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic plasma levels have not yet been defined",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F200297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Deprefax (AR);",
"     </li>",
"     <li>",
"      Dutonin (AT, ES, GB, IE);",
"     </li>",
"     <li>",
"      Menfazona (ES);",
"     </li>",
"     <li>",
"      Nefadar (CH, DE, DK, NO, SE);",
"     </li>",
"     <li>",
"      Nefaril (UY);",
"     </li>",
"     <li>",
"      Nefazodone &rdquo;BMS&rdquo; (AT);",
"     </li>",
"     <li>",
"      Reseril (IT);",
"     </li>",
"     <li>",
"      Rulivan (ES);",
"     </li>",
"     <li>",
"      Serzone (AU, BB, BM, BR, BS, BZ, GY, JM, NL, NZ, PL, SR, TT, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F200271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits neuronal reuptake of serotonin and norepinephrine; also blocks 5-HT",
"     <sub>",
"      2",
"     </sub>",
"     and alpha",
"     <sub>",
"      1",
"     </sub>",
"     receptors; has no significant affinity for alpha",
"     <sub>",
"      2",
"     </sub>",
"     , beta-adrenergic, 5-HT",
"     <sub>",
"      1A",
"     </sub>",
"     , cholinergic, dopaminergic, or benzodiazepine receptors",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F200291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Therapeutic: Up to 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.22-0.87 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to three active metabolites: Triazoledione, hydroxynefazodone, and m-chlorophenylpiperazine (mCPP)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 20% (variable)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Parent drug: 2-4 hours; active metabolites persist longer",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1 hour, prolonged in presence of food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine (as metabolites); feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Committee on Practice Bulletins--Obstetrics, \"ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 92, April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 111(4):1001-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/0/2057/abstract-text/18378767/pubmed\" id=\"18378767\" target=\"_blank\">",
"        18378767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Psychiatric Association, \"Treatment Recommendations for Patients With Major Depressive Disorder,\" 3rd ed, May 2010. Available at file://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bandelow B, Zohar J, Hollander E, et al, &ldquo;World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders -- First Revision,&rdquo;",
"      <i>",
"       World J Biol Psychiatry",
"      </i>",
"      , 2008, 9(4): 248-312. Available at file://www.wfsbp.org/fileadmin/pdf/guides/Guidelines_Anxiety_revision.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/0/2057/abstract-text/18949648/pubmed\" id=\"18949648\" target=\"_blank\">",
"        18949648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benedek DM, Friedman MJ, Zatzick D, et al, &ldquo;Guideline Watch (March 2009): Practice Guideline for the Treatment of Patients With Acute Stress Disorder and Posttraumatic Stress Disorder.&rdquo; Available at  file://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file=AcuteStressDisorder-PTSD_GuidelineWatch",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dodd S, Maguire KP, Burrows GD, et al, \"Nefazodone in the Breast Milk of Nursing Mothers: A Report of Two Patients,\"",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2000, 20(6):717-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/0/2057/abstract-text/11106156/pubmed\" id=\"11106156\" target=\"_blank\">",
"        11106156",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Einarson A, Bonari L, Voyer-Lavigne S, et al, \"A Multicentre Prospective Controlled Study to Determine the Safety of Trazodone and Nefazodone Use During Pregnancy,\"",
"      <i>",
"       Can J Psychiatry",
"      </i>",
"      , 2003, 48(2):106-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/0/2057/abstract-text/12655908/pubmed\" id=\"12655908\" target=\"_blank\">",
"        12655908",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Einarson A, Choi J, Einarson TR, et al, \"Incidence of Major Malformations in Infants Following Antidepressant Exposure in Pregnancy: Results of a Large Prospective Cohort Study,\"",
"      <i>",
"       Can J Psychiatry",
"      </i>",
"      , 2009, 54(4):242-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/0/2057/abstract-text/19321030/pubmed\" id=\"19321030\" target=\"_blank\">",
"        19321030",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fontaine R, Ontiveros A, Elie R, et al, &ldquo;A Double-Blind Comparison of Nefazodone, Imipramine, and Placebo in Major Depression,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1994, 55(6):234-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/0/2057/abstract-text/8071277/pubmed\" id=\"8071277\" target=\"_blank\">",
"        8071277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/0/2057/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson JC and Devanand DP, \"A Systematic Review and Meta-Analysis of Placebo-Controlled Antidepressant Studies in People With Depression and Dementia,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2011, 59(4):577-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/0/2057/abstract-text/21453380/pubmed\" id=\"21453380\" target=\"_blank\">",
"        21453380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/0/2057/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rickels K, Schweizer E, Clary C, et al, &ldquo;Nefazodone and Imipramine in Major Depression: A Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Br J Psychiatry",
"      </i>",
"      , 1994, 164(6):802-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/0/2057/abstract-text/7952987/pubmed\" id=\"7952987\" target=\"_blank\">",
"        7952987",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shea JP, Shulka UA, Rittman KA, &ldquo;Single Dose Pharmacokinetics of Nefazodone in Elderly Subjects, Renally Impaired Patients, and Patients With Hepatic Cirrhosis in Comparison to Healthy Volunteers,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1988, 43:146.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilens TE, Spencer TJ, Biederman J, et al, &ldquo;Case Study: Nefazodone for Juvenile Mood Disorders,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1997, 36(4):481-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/0/2057/abstract-text/9100422/pubmed\" id=\"9100422\" target=\"_blank\">",
"        9100422",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yapp P, Ilett KF, Kristensen JH, et al, \"Drowsiness and Poor Feeding in a Breast-Fed Infant: Association With Nefazodone and Its Metabolites,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2000, 34(11):1269-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/0/2057/abstract-text/11098340/pubmed\" id=\"11098340\" target=\"_blank\">",
"        11098340",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yonkers KA, Wisner KL, Stewart DE, et al, &ldquo;The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2009, 114(3):703-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/0/2057/abstract-text/19701065/pubmed\" id=\"19701065\" target=\"_blank\">",
"        19701065",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9684 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-18C9BB78CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_0_2057=[""].join("\n");
var outline_f2_0_2057=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709167\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200339\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200312\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200313\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200284\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200268\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874745\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200289\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200288\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200335\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200348\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200337\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200292\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200272\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200333\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200277\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200305\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200279\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5722223\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200317\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200296\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200295\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200281\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200285\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200297\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200271\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200291\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9684\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9684|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/61/42965?source=related_link\">",
"      Nefazodone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/7/1145?source=related_link\">",
"      Nefazodone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_0_2058="Epidemiology, treatment, and prognosis of medulloblastoma";
var content_f2_0_2058=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, treatment, and prognosis of medulloblastoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/0/2058/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/0/2058/contributors\">",
"     Scott L Pomeroy, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/0/2058/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/0/2058/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/0/2058/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/0/2058/contributors\">",
"     Amar Gajjar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/0/2058/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/0/2058/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/0/2058/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 15, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medulloblastomas are the most common malignant brain tumor of childhood and occur exclusively in the cerebellum. The disease is rare after the fourth decade of life.",
"   </p>",
"   <p>",
"    The epidemiology, clinical presentation, diagnosis, and treatment of medulloblastoma in children and adults, its prognosis, and the delayed complications in survivors are discussed here. The histopathology and molecular pathogenesis of medulloblastoma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41332?source=see_link\">",
"     \"Histopathology and molecular pathogenesis of medulloblastoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 500 children are diagnosed with a medulloblastoma each year in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/1\">",
"     1",
"    </a>",
"    ]. Medulloblastoma is the most common malignant brain tumor of childhood, accounting for approximately 20 percent of all primary tumors of the central nervous system among children less than 19 years of age. The peak incidence is in children between five and nine years of age. Approximately 70 percent of patients are diagnosed before the age of 20. There is a slight increase in incidence between the ages of 20 to 24 years, and the disease is rare after the fourth decade, consistent with its embryonal origin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medulloblastomas most commonly present with signs of increased intracranial pressure, including nocturnal or morning headaches, nausea, vomiting, and altered mental status. Since the tumors typically arise in the cerebellar midline, or more laterally in the cerebellar hemispheres in adults, truncal ataxia, head titubation (or bobbing), and unsteady gait are also common.",
"   </p>",
"   <p>",
"    Cranial nerve deficits may occur in conjunction with these signs, either from direct involvement of specific nerves or from cranial nerve dysfunction due to increased intracranial pressure. As examples, elevated intracranial pressure can induce dysfunction of the abducens nerves, causing diplopia especially with lateral gaze. Prolonged elevation of intracranial pressure can lead to permanent damage of the optic nerve with complete or partial loss of vision. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient with signs or symptoms suggestive of a cerebellar tumor should undergo magnetic resonance imaging. If medulloblastoma is suspected, contrast enhanced magnetic resonance imaging (MRI) of the entire neuroaxis and lumbar puncture should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging reveals a contrast-enhancing midline or paramedian tumor which often compresses the fourth ventricle (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55787 \" href=\"UTD.htm?32/41/33427\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/2\">",
"     2",
"    </a>",
"    ]. Gadolinium enhancement is often heterogeneous, and there may be regions of necrosis, hemorrhage, or cystic changes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Enhancing nodules or more linear patterns of enhancement also may be evident in the ventricles, over the surface of the brain, or in the spinal canal. Thus, contrast enhanced MRI of the entire neuroaxis, including the spine, should always be performed once the diagnosis of medulloblastoma is suspected. Medulloblastomas infrequently metastasize outside the nervous system, most often to the bone marrow.",
"   </p>",
"   <p>",
"    Adults are more likely to have cerebellar hemisphere tumors than are children, and the desmoplastic variant in adults may lack contrast enhancement.",
"   </p>",
"   <p>",
"    Medulloblastomas may be missed on CT scan and are invisible on skull films. The classic CT finding is a hyperdense mass on an unenhanced study that markedly enhances after the injection of contrast medium [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-third of medulloblastomas metastasize throughout the central nervous system following cerebral spinal fluid (CSF) pathways. In these cases, neoplastic cells may be present in the CSF. A positive CSF cytology either pre- or postoperatively predicts for an increased rate of relapse and poor outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In one series of 75 patients, for example, the 40 with positive CSF cytology had a significantly higher relapse rate than those with negative CSF cytology (70 versus 40 percent, p = 0.004) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/5\">",
"     5",
"    </a>",
"    ]. However, negative cytology does not exclude a more advanced stage of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appropriate initial treatment of patients with medulloblastoma includes the management of increased intracranial pressure and specific therapy directed against the tumor.",
"   </p>",
"   <p>",
"    Based upon results from multiple cooperative group trials, optimal treatment of medulloblastoma directed at the tumor includes a combination of maximal surgical resection, radiation therapy (RT) to both the tumor site and the craniospinal axis, and systemic chemotherapy. The application of this combined modality approach to different age groups is discussed below. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Average-risk children'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H19\">",
"     'Infants and young children'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H28\">",
"     'Adults'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Increased intracranial pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with medulloblastoma not uncommonly present with increased intracranial pressure due to obstructive hydrocephalus from compression of the fourth ventricle by the expanding tumor. Placement of a cerebrospinal fluid (CSF) shunt to relieve hydrocephalus is usually deferred until surgical resection since surgery alone is often sufficient to treat this problem.",
"   </p>",
"   <p>",
"    Local swelling from the tumor can contribute to symptoms of increased intracranial pressure. This vasogenic tumor edema is typically relieved by treatment with corticosteroids. The management of increased intracranial pressure is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"     \"Elevated intracranial pressure in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is used to remove as much of the tumor as possible without causing serious neurologic sequelae (eg, persistent ataxia, cranial nerve deficits). Because of the potential for neurologic complications, total or radical resection is not always possible [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who undergo a gross total or subtotal resection for nonmetastatic medulloblastoma have a better outcome than those who have a biopsy alone followed by RT [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. This was illustrated in two series, in which the five-year actuarial survival was higher in patients with complete or subtotal gross resection compared to biopsy alone (69 versus 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/9\">",
"     9",
"    </a>",
"    ], and 78 versus 43 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/10\">",
"     10",
"    </a>",
"    ]). Posterior fossa local control rates are also higher in those who are managed with complete or subtotal resection (83 and 89 versus 27 percent with biopsy alone) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy is an integral component of the initial management of patients with medulloblastoma, both to control residual posterior fossa disease and to treat any disease that has spread along the craniospinal axis. However, toxicity to the brain and spinal cord limits the doses used. This is particularly true in very young children, for whom craniospinal radiation is avoided or delayed due to severe toxicity to the rapidly developing central nervous system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;After surgical excision, medulloblastomas are treated with external beam RT to the craniospinal axis, with an additional boost to the tumor site [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/9,11,12\">",
"     9,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rationale for additional radiation to the tumor bed is based upon the observation that 50 to 70 percent of recurrences occur in the posterior fossa [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Although some investigators include the entire posterior fossa in the boost volume, posterior fossa failures are primarily in the tumor bed and are often associated with leptomeningeal failure. Local failure in the posterior fossa outside the tumor bed is rare as the solitary site of failure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Investigational approaches are examining the utility of proton beam and intensity-modulated RT [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using conventional techniques, the brain and spine are treated with separate but abutting RT fields. Placement of the junction between these two fields must be done precisely. Adjusting the site where these two fields abut each other two or three times during the course of craniospinal irradiation is routinely done to minimize the potential of overlapping dose to the spinal cord.",
"   </p>",
"   <p>",
"    However, sparing the spinal cord increases the dose to the thyroid gland, mandible, pharynx, and larynx. In developing children, this may increase the risk of late hypothyroidism or mandibular hypoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/18\">",
"     18",
"    </a>",
"    ]. Newer techniques, such as intensity modulated RT, are being evaluated to limit radiation to normal tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although higher doses of RT are associated with better tumor control [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/9,19\">",
"     9,19",
"    </a>",
"    ], irradiation of the craniospinal axis in children is associated with a significant incidence of neurologic complications, including neurocognitive impairment. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H25#H25\">",
"     \"Complications of cranial irradiation\", section on 'Neurocognitive effects in children'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/1/7190?source=see_link\">",
"     \"Complications of spinal cord irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whenever possible, RT is delayed for children younger than three years of age to permit further development of the central nervous system. For older children, the dose of RT is minimized. The potential negative impact from the combined effects of the tumor and treatment was illustrated by a study of 222 children irradiated for a brain tumor before the age of four; only one-third of adult survivors were able to have full-time employment and a normal life-style [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/20\">",
"     20",
"    </a>",
"    ]. Because of this, attempts to limit dose to the craniospinal axis when possible have become standard.",
"   </p>",
"   <p>",
"    In addition to its effects on neurocognitive development, craniospinal RT can cause decreased skeletal growth resulting in significantly decreased adult height [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/21\">",
"     21",
"    </a>",
"    ]. This effect appears to be mediated by decreased levels of growth hormone and may be partially avoided with decreased doses of radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/22\">",
"     22",
"    </a>",
"    ]. The risk of other delayed effects of RT, including hypothyroidism, adrenal insufficiency, and hypogonadism, may also be minimized with lower doses of RT. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Delayed complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because of the risks of serious complications, the initial management of pediatric patients with medulloblastoma has utilized adjuvant chemotherapy with decreased doses of RT in average-risk children or substituted chemotherapy for RT in the initial management of infants and young children. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Average-risk children'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H19\">",
"     'Infants and young children'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy has an important role in the multimodality management of children with medulloblastoma in several settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In average-risk children, adjuvant chemotherapy is used following surgery and RT to decrease the incidence of recurrence and minimize craniospinal radiation exposure. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Average-risk children'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In young children, chemotherapy is used after surgery to delay or avoid irradiating the developing brain and spinal cord. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Infants and young children'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Chemotherapy is used with RT to treat advanced stage disease that is not amenable to surgical resection. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Advanced-stage disease'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CHILDREN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combined modality approach to the treatment of children with medulloblastoma has evolved in a stepwise fashion. Prior to use of radiation, no children survived with surgical resection alone as therapy. Radiation therapy was incorporated to reduce the rate of local recurrence in the surgical bed and along the craniospinal axis (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Radiation therapy'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Subsequent multicenter randomized trials integrated chemotherapy along with radiation therapy following surgical resection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/12,23-26\">",
"     12,23-26",
"    </a>",
"    ]. Although randomized trials did not demonstrate a statistically significant benefit to overall survival, subset analyses suggested that chemotherapy did improve survival in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. A subsequent trial demonstrated an improvement in event-free survival, although the difference in overall survival was not statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of these trials included children with varying levels of risk for recurrence. Furthermore, advances in imaging, surgery, and radiotherapy techniques limit comparison of current results with those of earlier trials, in terms of both tumor control and complication outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Average-risk children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current approach to children age &ge;3 years of age with medulloblastoma that is amenable to total or near-total resection includes surgery, followed by craniospinal irradiation, and then adjuvant chemotherapy. The results of this approach in this patient subset are illustrated by the Children's Oncology Group trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Children's Oncology Group trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2006, the Children's Oncology Group (COG) published results from a large trial, which has defined the current standard of care for children with average-risk medulloblastoma and illustrates the outcomes using a combined modality approach that includes surgery, RT, and chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/26\">",
"     26",
"    </a>",
"    ]. This phase III trial included 421 children who had undergone complete or nearly complete surgical resection (residual disease &lt;1.5 cm",
"    <sup>",
"     2",
"    </sup>",
"    on postoperative imaging). Patients were required to have no evidence of disseminated disease on MRI and a negative cytologic examination of cerebrospinal fluid.",
"   </p>",
"   <p>",
"    Following surgery, children were treated with 23.4 Gy of craniospinal RT, followed by a posterior fossa boost of 32.4 Gy, for a total RT dose of 55.8 Gy to the tumor bed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/26\">",
"     26",
"    </a>",
"    ]. Children received weekly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    during RT. After completion of RT, patients were randomly assigned to eight cycles of chemotherapy with one of two regimens (vincristine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , plus CCNU, or vincristine, cisplatin, plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For the entire cohort of 379 evaluable children, the five-year event-free and overall survival rates were 81 and 86 percent, respectively, at a median follow-up of over five years. There were no significant differences between the two chemotherapy regimens. In addition, in 15 patients who were treated according to the protocol but were deemed to be ineligible at subsequent review based upon the presence of excess residual disease or disseminated disease at randomization, the five-year event-free survival was only 36 percent.",
"   </p>",
"   <p>",
"    The event-free survival in average-risk patients in this trial incorporating adjuvant chemotherapy is superior to that previously seen in trials using RT alone, even when a higher dose of RT is used [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/12,19\">",
"     12,19",
"    </a>",
"    ]. The results are also at least as good as those seen in trials using more intensive chemotherapy regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/25,27\">",
"     25,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Toxicity associated with treatment in these children included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Virtually all patients experienced acute grade 3 or 4 hematologic toxicity during treatment.",
"     </li>",
"     <li>",
"      Ototoxicity was seen in approximately 25 percent of patients.",
"     </li>",
"     <li>",
"      Approximately 25 percent of patients had significant neurologic sequelae from their surgery and RT, which persisted at one year in about one-half [",
"      <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Second malignancies were diagnosed in seven children (four second primary tumors in the central nervous system, two hematologic malignancies, and one basal cell carcinoma) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/26\">",
"       26",
"      </a>",
"      ]. Additional second malignancies may occur with further observation and additional follow-up will be required to estimate the risk of this complication.",
"     </li>",
"     <li>",
"      Evaluation of neurocognitive impairment in survivors has not yet been reported. Based upon results from other studies using this dose level of RT, significant neurocognitive impairment is expected to be seen, particularly in younger children [",
"      <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H25#H25\">",
"       \"Complications of cranial irradiation\", section on 'Neurocognitive effects in children'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Detailed evaluation of endocrine outcomes has not been reported, but a significant frequency of such abnormalities is anticipated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H38#H38\">",
"       \"Complications of cranial irradiation\", section on 'Endocrinopathies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Future directions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the neurologic toxicity associated with this dose of RT in other studies, the ongoing medulloblastoma trial of the COG is randomly assigning children age three to seven years old to craniospinal RT at a dose of either 18 or 23.4 Gy; older children continuing to receive 23.4 Gy. All patients are then independently randomized to receive whole posterior fossa boost RT versus a more limited volume defined by the tumor bed boost. All patients have the boost volume brought to a total dose of 54 Gy. This trial will look at both event-free survival and toxicity as end points.",
"   </p>",
"   <p>",
"    Whenever possible children with medulloblastoma should be enrolled in a protocol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Infants and young children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children &le;3 years of age with medulloblastoma are at high risk of severe neurologic impairment if their initial treatment includes craniospinal RT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H25#H25\">",
"     \"Complications of cranial irradiation\", section on 'Neurocognitive effects in children'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies have used chemotherapy to delay or obviate the need for RT, and thereby allow the nervous system an opportunity to develop further [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/21,29-37\">",
"     21,29-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three large multicenter studies illustrate this approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a French series of 79 children younger than five years, patients were treated with a four-drug combination chemotherapy regimen that did not include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/35\">",
"       35",
"      </a>",
"      ]. RT was given only if relapse occurred. Among the 47 patients who had a gross total resection, 14 were alive in their first complete remission, including 13 who had not received RT. In contrast, among the 32 children with either residual disease following surgery or with metastases, only two were alive in their first complete remission without having received RT.",
"     </li>",
"     <li>",
"      A trial from the Children's Cancer Group treated 299 children younger than three years of age with brain tumors, including 92 with medulloblastoma [",
"      <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/37\">",
"       37",
"      </a>",
"      ]. Patients were treated with one of two four-drug combination chemotherapy regimens, and RT was withheld unless there was evidence of tumor progression. At five years, 10 of 38 children who had M0 disease (",
"      <a class=\"graphic graphic_table graphicRef73044 \" href=\"UTD.htm?10/31/10748\">",
"       table 1",
"      </a>",
"      ) were alive and event-free without having received RT. Among patients with more extensive residual disease or with metastases, only 9 of 54 were event-free without RT.",
"     </li>",
"     <li>",
"      Somewhat better results were seen in a study of 43 children with medulloblastoma (all &le;3 years of age), who received a more intensive five-drug chemotherapy regimen plus intraventricular",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      following surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/34\">",
"       34",
"      </a>",
"      ]. Treatment was discontinued after three cycles if patients were in complete remission. Further surgery, RT,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      experimental chemotherapy were administered to children with progressive or residual disease or who subsequently relapsed. The five-year overall survival and PFS rates were 66 and 58 percent, respectively. Patients had significantly lower results on neurocognitive evaluation compared to healthy children of the same age. However, the impairment was less severe than in children in other series who received RT as a component of their initial therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The long-term effectiveness of substituting chemotherapy for RT in controlling the tumor remains uncertain. In addition, there is a concern that the intensive use of chemotherapy in young children may increase the risk of a second malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Advanced-stage disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment for children with metastatic or unresectable medulloblastoma is unknown.",
"   </p>",
"   <p>",
"    In the largest trial in this setting, the Children's Cancer Study Group randomly assigned 283 children with advanced stage, unresected medulloblastoma to receive either a standard regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , CCNU, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (VCP) following RT, or a more intensive chemotherapy that included \"eight drugs in one day\" (8-in-1), both before and after RT [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/39\">",
"     39",
"    </a>",
"    ]. RT followed by VCP was superior to the 8-in-1 chemotherapy regimen with five-year progression-free survival of 63 and 45 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Recurrent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the improved prognosis for children with medulloblastoma, an estimated 20 to 30 percent will relapse following their initial treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High-dose chemotherapy with autologous stem cell rescue has been studied by multiple groups in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. In small series, this approach has resulted in prolonged disease-free survival in approximately 20 to 25 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific inhibition of molecular targets, such as the sonic hedgehog pathway, that are involved in the pathogenesis of medulloblastoma, also appears promising in preliminary reports [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41332?source=see_link&amp;anchor=H5#H5\">",
"     \"Histopathology and molecular pathogenesis of medulloblastoma\", section on 'SHH pathway'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Delayed complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each component of treatment can cause delayed complications that have a profound effect on quality of life in medulloblastoma survivors. Although the late effects of treatment on quality of life are often attributed to craniospinal irradiation, one study found that chemotherapy has a significant role in aggravating the adverse effects of RT [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/12,45\">",
"     12,45",
"    </a>",
"    ]. In a series of 108 patients surviving without evidence of active disease, patients treated with chemotherapy plus RT had a significantly poorer overall health status compared to those treated with RT alone at a mean follow-up of seven years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific long-term follow-up guidelines for survivors of childhood CNS tumors have been published by the Children's Oncology Group and are available at",
"    <a class=\"external\" href=\"file://www.survivorshipguidelines.org/\">",
"     www.survivorshipguidelines.org",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the most important complications are the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Neurocognitive impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurocognitive impairment can be observed following treatment with postoperative RT, particularly in young children; this can be severe. Neurocognitive impairment may be further exacerbated when the chemotherapy includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H25#H25\">",
"     \"Complications of cranial irradiation\", section on 'Neurocognitive effects in children'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Hearing loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hearing loss may be due either to RT or to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    chemotherapy regimens. Ototoxicity is a significant risk given the doses of RT used in medulloblastoma protocols, and there may be synergistic toxicity between RT and cisplatin chemotherapy. Enhanced utilization of intensity modulation with assiduous attention to avoidance of otic structures may diminish the incidence of this side effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H36#H36\">",
"     \"Complications of cranial irradiation\", section on 'Ototoxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data from a nonrandomized study suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"     amifostine",
"    </a>",
"    may decrease the incidence of severe (&gt;25 dB at 2000 Hz) ototoxicity in children treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37242?source=see_link&amp;anchor=H7#H7\">",
"     \"Neurologic complications of platinum-based chemotherapy\", section on 'Ototoxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, a slowly progressive sensorineural hearing loss and ataxia has been reported developing years after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/48\">",
"     48",
"    </a>",
"    ]. In some cases, this has been found to occur in association with a hypointense rim of iron coating the surface of the cerebellum and brainstem and has been called superficial siderosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Endocrine abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of endocrine abnormalities have been described following RT for medulloblastoma. Irradiation of the pituitary hypothalamic axis can result in growth hormone (GH), adrenocorticotrophic hormone (ACTH), and thyroid-stimulation hormone (TSH) deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/49\">",
"     49",
"    </a>",
"    ]. In addition, irradiation of the thyroid can cause primary hypothyroidism. Hypogonadism and early puberty have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of endocrine abnormalities was illustrated by a prospective series of 88 children treated between 1996 and 2003 at St Jude Children's Research Hospital for embryonal brain tumors, including 78 (89 percent) with medulloblastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/49\">",
"     49",
"    </a>",
"    ]. All patients underwent detailed endocrinologic evaluation and were followed for a minimum of one year.",
"   </p>",
"   <p>",
"    The following findings were noted at a median follow-up of 1.5 to 1.8 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      GH deficiency was present in 94 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31607?source=see_link\">",
"       \"Growth failure after childhood cancer: Role of growth hormone deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      TSH deficiency was present in 10 percent overall and was more frequent in those receiving higher doses of radiation to the hypothalamus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=see_link&amp;anchor=H3#H3\">",
"       \"Acquired hypothyroidism in childhood and adolescence\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary hypothyroidism was present in 50 percent, but was less common in average-risk patients, who received lower doses of radiation (four-year incidence 13 versus 54 percent in high-risk patients who received higher doses of irradiation). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=see_link&amp;anchor=H12#H12\">",
"       \"Acquired hypothyroidism in childhood and adolescence\", section on 'Craniospinal irradiation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ACTH deficiency was present in 43 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27238?source=see_link\">",
"       \"Causes and clinical manifestations of central adrenal insufficiency in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Secondary cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of second malignancies is increased in children following RT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy for primary central nervous system malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/26,38,50-53\">",
"     26,38,50-53",
"    </a>",
"    ]. These secondary tumors may be diagnosed many years after the original presentation; the magnitude of this risk is not known. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Children's Oncology Group trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Posterior fossa syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posterior fossa syndrome, also called cerebellar mutism, is a distinctive postoperative complication that is caused by injury to the cerebellar vermis or dentate nuclei. This complication is characterized by impaired language production in association with emotional lability [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. The most severely affected individuals also have varying degrees of inattention or difficulty initiating movement. Other associated postoperative neurologic symptoms include cranial nerve palsies or bowel and bladder incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Posterior fossa syndrome can appear one to two days after surgery. Symptoms frequently resolve over the course of weeks to months, although some patients may not fully recover language skills for months or years. In a prospective study of 450 children from the Children's Oncology Group study, 24 percent had symptoms consistent with posterior fossa syndrome, and 92 percent of these were moderately to severely affected [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     ADULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, medulloblastoma constitutes less than 3 percent of brain tumors. Anaplastic features may be less common in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/59\">",
"     59",
"    </a>",
"    ], but late relapses, lateral tumor location, and desmoplastic histologic features are more common [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Because of the rarity of medulloblastoma in this age group, therapy is patterned after that in children [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41332?source=see_link\">",
"     \"Histopathology and molecular pathogenesis of medulloblastoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most extensive prospective experience in treating adults (age greater than 18 years) with medulloblastoma comes from a phase II study that enrolled 95 patients over a 20 year period [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/63\">",
"     63",
"    </a>",
"    ]. The 30 low-risk patients (no residual disease following surgical resection) were treated with craniospinal RT (36 Gy) followed by an RT boost to the tumor site (18.8 Gy for a total of 54.8 Gy). High-risk patients (residual disease following surgery or distant metastases) received two cycles of combination chemotherapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) followed by the same RT regimen. Those with metastases were then given maintenance chemotherapy.",
"   </p>",
"   <p>",
"    Results were presented at the 2010 American Society of Clinical Oncology (ASCO) meeting. For low-risk patients, the 10-year progression-free survival (PFS) and overall survival (OS) rates were 46 and 65 percent, respectively. For those with high-risk disease, the 10-year PFS and OS rates were 36 and 45 percent, respectively.",
"   </p>",
"   <p>",
"    Similar outcomes were reported by a Surveillance, Epidemiology and End Results (SEER) database study of 454 patients treated between 1970 and 2004, which found 5- and 10-year survival rates of 65 and 52 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/64\">",
"     64",
"    </a>",
"    ]. Multivariable regression modeling found that diagnosis after 1980, age less than 20 years, and gross total resection at diagnosis were associated with a better prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important factors affecting outcome are the extent of disease and the age of the patient at diagnosis. These factors have been used to define risk groups and adapt therapy. Recent studies are defining the importance of both molecular markers and histopathology in determining prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/65,66\">",
"     65,66",
"    </a>",
"    ], and these may form the basis for better pretreatment risk stratification [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Molecular markers are being evaluated and may eventually permit further refinement in the choice of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Extent of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The modified Chang criteria, based upon the extent of the primary medulloblastoma and associated metastases, are used to estimate prognosis, which is progressively worse in the presence of more advanced disease (",
"    <a class=\"graphic graphic_table graphicRef73044 \" href=\"UTD.htm?10/31/10748\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The spinal cord is a frequent site of spread, with involvement at presentation in 20 to 25 percent of patients. Contrast-enhanced magnetic resonance imaging (MRI) and CSF cytology are used to assess the craniospinal axis; this approach has replaced myelography [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. Staging is usually performed within one to two weeks after surgery. If CSF is obtained post-operatively it is important to wait two weeks to avoid potential contamination of the specimen with surgical debris.",
"   </p>",
"   <p>",
"    The importance of the presence of metastases was illustrated in a trial of 188 children with medulloblastoma. Patients without metastatic disease (M0) had a significantly higher five-year progression-free survival (PFS) (70 percent versus 57 percent with M1 and 40 percent with M2, M3, or M4 disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/39\">",
"     39",
"    </a>",
"    ]. Similar results were noted in a second series of 173 consecutive patients with medulloblastoma, 84 percent of whom were less than 15 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/72\">",
"     72",
"    </a>",
"    ]. The five-year survival of those with M0 or M1 disease was 78 percent compared to 21 percent in patients with M2 or M3 involvement.",
"   </p>",
"   <p>",
"    Extraneural metastases are rare. In a review of the literature that identified 119 patients with M4 disease, the median age was 16 years, and the median time to diagnosis after initial presentation was 16 months [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/73\">",
"     73",
"    </a>",
"    ]. Bone was the most common site of extraneural disease and was present in 84 percent of cases. In approximately one-half of patients, CNS involvement was present at the time of extraneural relapse. Negative prognostic factors included the presence of lung or liver metastases, the presence of CNS disease, and a shorter interval between original diagnosis and the development of these metastases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Age at diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Young age at diagnosis has a negative impact on both long-term survival and quality of life in survivors. Children younger than age five years with medulloblastoma, and particularly those younger than three, have a significantly poorer prognosis. This was illustrated by one series, in which the estimated five-year PFS was 32 percent between age 1.5 and three years versus 58 percent in those three and older [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children diagnosed with medulloblastoma younger than age three years typically are treated with regimens that avoid or delay craniospinal radiation, because radiation is particularly damaging to the developing nervous system at this young age. Reduction or elimination of radiation in very young children may contribute to their overall poor prognosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H25#H25\">",
"     \"Complications of cranial irradiation\", section on 'Neurocognitive effects in children'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although increased doses of RT can improve disease control, it is unlikely that this approach can be used to prolong survival in young children since the doses of RT to the craniospinal axis required for a higher control rate lead to progressively worse neurologic outcome. Further improvements in the outcome for young patients will require the development of effective new treatments that do not harm the developing nervous system. Limiting the volume treated with RT may be another potential approach for improvement. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Radiation therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The natural history and response to treatment of medulloblastoma may differ in older as compared to younger children. In a retrospective review of 72 patients between the ages of 10 and 20 years at the time of diagnosis, five-year overall and event-free survival rates of 78 and 70 percent, respectively, were similar to those observed in younger children [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/74\">",
"     74",
"    </a>",
"    ]. However, relapses were often delayed with a mean time to relapse of three years. Furthermore, treatment in this older cohort was associated with frequent severe toxicity, including ototoxicity, peripheral neuropathy, hematologic toxicity, and weight loss (in 45, 71, 95, and 73 percent of patients, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1141086016\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization classification of brain tumors divides medulloblastoma based upon histopathologic criteria into several variants, including classic,",
"    <span class=\"nowrap\">",
"     desmoplastic/nodular,",
"    </span>",
"    desmoplastic with extensive nodularity, large cell, or anaplastic [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/66,75\">",
"     66,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histopathology is an important prognostic factor, particularly in young children. The impact of histopathology was studied in a cohort of 260 children less than five years of age who were treated on national protocols in Europe and the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/66\">",
"     66",
"    </a>",
"    ]. Even after accounting for stage (presence of metastases, residual disease), patients with",
"    <span class=\"nowrap\">",
"     desmoplastic/nodular",
"    </span>",
"    or desmoplastic with extensive nodularity had a significantly better event-free and overall survival compared with the classic form of medulloblastoma on multivariate analysis. In contrast, those with large cell or anaplastic variants had a significantly poorer prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Molecular markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analysis of molecular features in medulloblastoma may offer important insights into the prognosis, and thus provide opportunities to individualize treatment for patients with medulloblastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?2/0/2058/abstract/65-67,76-79\">",
"     65-67,76-79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These studies have shown that there is a complex genomic heterogeneity in medulloblastomas and that analyses of multiple markers can be used to identify subsets of medulloblastoma patients that may have an improved or worse prognosis. The molecular profiles of the subsets suggest that they each have specific molecular mechanisms of tumorigenesis, including activation of the Hedgehog pathway in one subset and the Wnt pathway in another. This in turn may eventually allow a more individualized approach to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined modality therapy, including surgery, craniospinal radiation therapy (RT), and chemotherapy is the standard of care for both children and adults. Patients should be treated in clinical trials whenever possible.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Average-risk children - The average-risk subset includes children &ge;3 years of age who have undergone a complete or near complete resection, have a negative cerebrospinal fluid cytology, and have no evidence of distant metastases. If these children cannot be included in a formal clinical trial, we recommend combined modality treatment including both craniospinal RT and adjuvant chemotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Average-risk children'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The protocol used in the Children's Oncology Group medulloblastoma trial is the current standard. After gross total resection of the tumor, patients are treated with 23.4 Gy to the craniospinal axis with a posterior fossa boost to a total dose of 55.8 Gy. This is followed by eight cycles of chemotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      or CCNU. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Children's Oncology Group trial'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants and young children - Children &le;3 years of age with medulloblastoma are at high risk of severe neurologic impairment if their initial treatment includes craniospinal RT. We recommend that treatment in this age group be done on approved protocols that utilize combination chemotherapy to either delay or obviate the need for craniospinal RT (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Infants and young children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Advanced-stage, unresectable disease - The optimal treatment for children with metastatic, unresectable, or recurrent medulloblastoma is unknown; these patients should be included on a clinical protocol whenever possible. In the absence of a suitable clinical study, we suggest craniospinal RT followed by combination chemotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Advanced-stage disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adults - The clinical experience with medulloblastoma in adults is more limited, and treatment should be patterned after that in children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If these patients cannot be included in a formal clinical trial, we recommend combined modality treatment including both craniospinal RT and adjuvant chemotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Adults'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Average-risk children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal treatment for adults with metastatic, unresectable, or recurrent medulloblastoma is unknown. These patients should be included on a clinical protocol whenever possible. In the absence of a suitable clinical study, we suggest craniospinal RT followed by combination chemotherapy. (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Adults'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Advanced-stage disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/1\">",
"      McNeil DE, Cot&eacute; TR, Clegg L, Rorke LB. Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results. Med Pediatr Oncol 2002; 39:190.",
"     </a>",
"    </li>",
"    <li>",
"     Wolpert, SM, Barnes, PD. MRI in Pediatric Neuroradiology, Mosby, St. Louis 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/3\">",
"      Bourgouin PM, Tampieri D, Grahovac SZ, et al. CT and MR imaging findings in adults with cerebellar medulloblastoma: comparison with findings in children. AJR Am J Roentgenol 1992; 159:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/4\">",
"      Miralbell R, Bieri S, Huguenin P, et al. Prognostic value of cerebrospinal fluid cytology in pediatric medulloblastoma. Swiss Pediatric Oncology Group. Ann Oncol 1999; 10:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/5\">",
"      Perek D, Perek-Polnik M, Drogosiewicz M, et al. Risk factors of recurrence in 157 MB/PNET patients treated in one institution. Childs Nerv Syst 1998; 14:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/6\">",
"      Raimondi AJ, Tomita T. Medulloblastoma in childhood. Acta Neurochir (Wien) 1979; 50:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/7\">",
"      Park TS, Hoffman HJ, Hendrick EB, et al. Medulloblastoma: clinical presentation and management. Experience at the hospital for sick children, toronto, 1950-1980. J Neurosurg 1983; 58:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/8\">",
"      Berry MP, Jenkin RD, Keen CW, et al. Radiation treatment for medulloblastoma. A 21-year review. J Neurosurg 1981; 55:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/9\">",
"      Hughes EN, Shillito J, Sallan SE, et al. Medulloblastoma at the joint center for radiation therapy between 1968 and 1984. The influence of radiation dose on the patterns of failure and survival. Cancer 1988; 61:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/10\">",
"      del Charco JO, Bolek TW, McCollough WM, et al. Medulloblastoma: time-dose relationship based on a 30-year review. Int J Radiat Oncol Biol Phys 1998; 42:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/11\">",
"      Tarbell NJ, Loeffler JS, Silver B, et al. The change in patterns of relapse in medulloblastoma. Cancer 1991; 68:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/12\">",
"      Taylor RE, Bailey CC, Robinson K, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J Clin Oncol 2003; 21:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/13\">",
"      Fukunaga-Johnson N, Lee JH, Sandler HM, et al. Patterns of failure following treatment for medulloblastoma: is it necessary to treat the entire posterior fossa? Int J Radiat Oncol Biol Phys 1998; 42:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/14\">",
"      Wolden SL, Dunkel IJ, Souweidane MM, et al. Patterns of failure using a conformal radiation therapy tumor bed boost for medulloblastoma. J Clin Oncol 2003; 21:3079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/15\">",
"      St Clair WH, Adams JA, Bues M, et al. Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int J Radiat Oncol Biol Phys 2004; 58:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/16\">",
"      Yuh GE, Loredo LN, Yonemoto LT, et al. Reducing toxicity from craniospinal irradiation: using proton beams to treat medulloblastoma in young children. Cancer J 2004; 10:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/17\">",
"      Huang E, Teh BS, Strother DR, et al. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 2002; 52:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/18\">",
"      Narayana A, Jeswani S, Paulino AC. The cranial-spinal junction in medulloblastoma: does it matter? Int J Radiat Oncol Biol Phys 1999; 44:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/19\">",
"      Thomas PR, Deutsch M, Kepner JL, et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 2000; 18:3004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/20\">",
"      Jenkin D, Danjoux C, Greenberg M. Subsequent quality of life for children irradiated for a brain tumor before age four years. Med Pediatr Oncol 1998; 31:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/21\">",
"      Goldwein JW, Radcliffe J, Johnson J, et al. Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma). Int J Radiat Oncol Biol Phys 1996; 34:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/22\">",
"      Xu W, Janss A, Packer RJ, et al. Endocrine outcome in children with medulloblastoma treated with 18 Gy of craniospinal radiation therapy. Neuro Oncol 2004; 6:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/23\">",
"      Evans AE, Jenkin RD, Sposto R, et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 1990; 72:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/24\">",
"      Tait DM, Thornton-Jones H, Bloom HJ, et al. Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 1990; 26:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/25\">",
"      Kortmann RD, K&uuml;hl J, Timmermann B, et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys 2000; 46:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/26\">",
"      Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006; 24:4202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/27\">",
"      K&uuml;hl J, M&uuml;ller HL, Berthold F, et al. Preradiation chemotherapy of children and young adults with malignant brain tumors: results of the German pilot trial HIT'88/'89. Klin Padiatr 1998; 210:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/28\">",
"      Robertson, PL, Murasko, KM, Packer, RJ, et al. Prospective study of the cerebellar mutism syndrome after posterior fossa surgery in two large cohorts of medulloblastoma. Ann Neurol 2002; 52:S115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/29\">",
"      Ris MD, Packer R, Goldwein J, et al. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study. J Clin Oncol 2001; 19:3470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/30\">",
"      Douglas JG, Barker JL, Ellenbogen RG, Geyer JR. Concurrent chemotherapy and reduced-dose cranial spinal irradiation followed by conformal posterior fossa tumor bed boost for average-risk medulloblastoma: efficacy and patterns of failure. Int J Radiat Oncol Biol Phys 2004; 58:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/31\">",
"      Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 1993; 328:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/32\">",
"      Kretschmar CS, Tarbell NJ, Kupsky W, et al. Pre-irradiation chemotherapy for infants and children with medulloblastoma: a preliminary report. J Neurosurg 1989; 71:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/33\">",
"      Walter AW, Mulhern RK, Gajjar A, et al. Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital. J Clin Oncol 1999; 17:3720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/34\">",
"      Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005; 352:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/35\">",
"      Grill J, Sainte-Rose C, Jouvet A, et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol 2005; 6:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/36\">",
"      Mason WP, Grovas A, Halpern S, et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 1998; 16:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/37\">",
"      Geyer JR, Sposto R, Jennings M, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol 2005; 23:7621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/38\">",
"      Duffner PK, Krischer JP, Horowitz ME, et al. Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study. Ann Neurol 1998; 44:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/39\">",
"      Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 1999; 17:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/40\">",
"      Kadota RP, Mahoney DH, Doyle J, et al. Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma. Pediatr Blood Cancer 2008; 51:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/41\">",
"      Dunkel IJ, Gardner SL, Garvin JH Jr, et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma. Neuro Oncol 2010; 12:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/42\">",
"      Graham ML, Herndon JE 2nd, Casey JR, et al. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol 1997; 15:1814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/43\">",
"      Packer RJ. Childhood medulloblastoma: progress and future challenges. Brain Dev 1999; 21:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/44\">",
"      Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 361:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/45\">",
"      Bull KS, Spoudeas HA, Yadegarfar G, et al. Reduction of health status 7 years after addition of chemotherapy to craniospinal irradiation for medulloblastoma: a follow-up study in PNET 3 trial survivors on behalf of the CCLG (formerly UKCCSG). J Clin Oncol 2007; 25:4239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/46\">",
"      Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004; 22:4979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/47\">",
"      Fouladi M, Chintagumpala M, Ashley D, et al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol 2008; 26:3749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/48\">",
"      Anderson NE, Sheffield S, Hope JK. Superficial siderosis of the central nervous system: a late complication of cerebellar tumors. Neurology 1999; 52:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/49\">",
"      Laughton SJ, Merchant TE, Sklar CA, et al. Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial. J Clin Oncol 2008; 26:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/50\">",
"      Garwicz S, Anderson H, Olsen JH, et al. Second malignant neoplasms after cancer in childhood and adolescence: a population-based case-control study in the 5 Nordic countries. The Nordic Society for Pediatric Hematology and Oncology. The Association of the Nordic Cancer Registries. Int J Cancer 2000; 88:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/51\">",
"      Stavrou T, Bromley CM, Nicholson HS, et al. Prognostic factors and secondary malignancies in childhood medulloblastoma. J Pediatr Hematol Oncol 2001; 23:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/52\">",
"      Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 2001; 93:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/53\">",
"      Devarahally SR, Severson RK, Chuba P, et al. Second malignant neoplasms after primary central nervous system malignancies of childhood and adolescence. Pediatr Hematol Oncol 2003; 20:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/54\">",
"      Wisoff JH, Epstein FJ. Pseudobulbar palsy after posterior fossa operation in children. Neurosurgery 1984; 15:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/55\">",
"      Rekate HL, Grubb RL, Aram DM, et al. Muteness of cerebellar origin. Arch Neurol 1985; 42:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/56\">",
"      Janssen G, Messing-J&uuml;nger AM, Engelbrecht V, et al. Cerebellar mutism syndrome. Klin Padiatr 1998; 210:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/57\">",
"      Siffert J, Poussaint TY, Goumnerova LC, et al. Neurological dysfunction associated with postoperative cerebellar mutism. J Neurooncol 2000; 48:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/58\">",
"      Robertson PL, Muraszko KM, Holmes EJ, et al. Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children's Oncology Group. J Neurosurg 2006; 105:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/59\">",
"      Rodriguez FJ, Eberhart C, O'Neill BP, et al. Histopathologic grading of adult medulloblastomas. Cancer 2007; 109:2557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/60\">",
"      Abacioglu U, Uzel O, Sengoz M, et al. Medulloblastoma in adults: treatment results and prognostic factors. Int J Radiat Oncol Biol Phys 2002; 54:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/61\">",
"      Chan AW, Tarbell NJ, Black PM, et al. Adult medulloblastoma: prognostic factors and patterns of relapse. Neurosurgery 2000; 47:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/62\">",
"      Padovani L, Sunyach MP, Perol D, et al. Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults. Int J Radiat Oncol Biol Phys 2007; 68:433.",
"     </a>",
"    </li>",
"    <li>",
"     Brandes, AA, Franceschi, E, Tosoni, A, et al. Efficacy of tailored treatment for high- and low-risk medulloblastoma in adults: A large prospective phase II trial (abstract #2003). J Clin Oncol 2010; 28:182s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/64\">",
"      Lai R. Survival of patients with adult medulloblastoma: a population-based study. Cancer 2008; 112:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/65\">",
"      Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011; 29:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/66\">",
"      Rutkowski S, von Hoff K, Emser A, et al. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. J Clin Oncol 2010; 28:4961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/67\">",
"      Ellison DW, Kocak M, Dalton J, et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 2011; 29:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/68\">",
"      Chang CH, Housepian EM, Herbert C Jr. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 1969; 93:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/69\">",
"      Deutsch M, Laurent JP, Cohen ME. Myelography for staging medulloblastoma. Cancer 1985; 56:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/70\">",
"      Flannery AM, Tomita T, Radkowski M, McLone DG. Medulloblastomas in childhood: postsurgical evaluation with myelography and cerebrospinal fluid cytology. J Neurooncol 1990; 8:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/71\">",
"      O'Reilly G, Hayward RD, Harkness WF. Myelography in the assessment of children with medulloblastoma. Br J Neurosurg 1993; 7:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/72\">",
"      Jenkin D, Shabanah MA, Shail EA, et al. Prognostic factors for medulloblastoma. Int J Radiat Oncol Biol Phys 2000; 47:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/73\">",
"      Mazloom A, Zangeneh AH, Paulino AC. Prognostic factors after extraneural metastasis of medulloblastoma. Int J Radiat Oncol Biol Phys 2010; 78:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/74\">",
"      Tabori U, Sung L, Hukin J, et al. Medulloblastoma in the second decade of life: a specific group with respect to toxicity and management: a Canadian Pediatric Brain Tumor Consortium Study. Cancer 2005; 103:1874.",
"     </a>",
"    </li>",
"    <li>",
"     Giangaspero, F, Eberhart, CG, Haapasalo, H, et, al.. Medulloblastoma. In: WHO Classification of Tumours of the Central Nervous System, 4th, Louis, DN, Ohgaki, H, Wiestler, OD, Cavenee, WK. (Eds), IARC, Lyon 2007. p.132.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/76\">",
"      Tabori U, Baskin B, Shago M, et al. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol 2010; 28:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/77\">",
"      Korshunov, A, Remke, M, Werft, W, et al. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol 2010; :.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/78\">",
"      Pfaff E, Remke M, Sturm D, et al. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol 2010; 28:5188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/0/2058/abstract/79\">",
"      Cho YJ, Tsherniak A, Tamayo P, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011; 29:1424.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5219 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-486B9E35E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_0_2058=[""].join("\n");
var outline_f2_0_2058=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PRINCIPLES OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Increased intracranial pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Average-risk children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Children's Oncology Group trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Future directions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Infants and young children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Advanced-stage disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Recurrent disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Delayed complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Neurocognitive impairment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Hearing loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Endocrine abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Secondary cancers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Posterior fossa syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      ADULTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Extent of disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Age at diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1141086016\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Molecular markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5219\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5219|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/41/33427\" title=\"diagnostic image 1\">",
"      Imaging medulloblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5219|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/31/10748\" title=\"table 1\">",
"      Chang staging medulloblastoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=related_link\">",
"      Acquired hypothyroidism in childhood and adolescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27238?source=related_link\">",
"      Causes and clinical manifestations of central adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/1/7190?source=related_link\">",
"      Complications of spinal cord irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=related_link\">",
"      Elevated intracranial pressure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31607?source=related_link\">",
"      Growth failure after childhood cancer: Role of growth hormone deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41332?source=related_link\">",
"      Histopathology and molecular pathogenesis of medulloblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37242?source=related_link\">",
"      Neurologic complications of platinum-based chemotherapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_0_2059="Muscle tone in colic PI";
var content_f2_0_2059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F76502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F76502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Symptoms of increased muscle tone in babies with colic",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        The baby's face is red, and the skin around the mouth is pale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The belly is bulging and hard",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The legs are drawn into the belly, and the feet are cold. (The legs can also be straight out when the baby cries especially hard.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The fingers are clenched shut",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The arms are stiff, tight, and straight. (The elbows can also be bent.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The back is arched",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Lester BM. Colic and Excessive Crying. Report of the 105th Ross Conference on Pediatric Research, Lester BM, Barr RG (Eds), Ross Products Division, Columbus, OH, 1997. p.18.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_0_2059=[""].join("\n");
var outline_f2_0_2059=null;
var title_f2_0_2060="Low-fat low-sugar guide B";
var content_f2_0_2060=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tips for maintaining a healthy weight: Low-fat, low-sugar eating guidelines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Food group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Food to choose more often",
"       </td>",
"       <td class=\"subtitle1\">",
"        Food to limit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fats",
"       </td>",
"       <td>",
"        Almonds, avocado, canola oil; fat-free or reduced-fat margarine, mayonnaise and salad dressings; olives, olive oil, peanut butter, peanuts, sunflower seeds, walnuts",
"       </td>",
"       <td>",
"        Bacon, butter, chitterlings, coconut; cream (half and half, whipped cream), cream cheese, saturated fats such as coconut, palm and palm kernel oils; shortening or lard, sour cream",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sweets",
"       </td>",
"       <td>",
"        Sugar substitutes such as Equal, Sweet 'n Low, or Splenda; light or sugar-free syrups, light or low-sugar jams and jellies; sugar-free gelatin; sugar-free Popsicles",
"       </td>",
"       <td>",
"        Candy, sugar, syrup, honey, jam, jelly, gelatin, Popsicles and fruit juice bars, fruit snacks and fruit leather",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beverages",
"       </td>",
"       <td>",
"        Water, diet sodas, sugar-free drink mixes, sugar-free flavored water, unsweetened iced tea, coffee",
"       </td>",
"       <td>",
"        Regular sodas, fruit juices, sports drinks, drink mixes, sweet tea, and flavored coffee beverages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Miscellaneous",
"       </td>",
"       <td>",
"        Catsup, mustard, pickles, salsa, spices, lemon juice",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Snacks (in very limited amounts)",
"       </td>",
"       <td>",
"        Low-fat popcorn, pretzels, baked or low-fat chips, rice cakes, graham crackers, granola bars, fat-free and low-fat frozen yogurt, fat-free fudge bars, homemade fruit smoothies",
"       </td>",
"       <td>",
"        Chips, buttered popcorn; store bought cakes, cookies and pies; chocolate, sherbet, ice cream, pudding",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_0_2060=[""].join("\n");
var outline_f2_0_2060=null;
var title_f2_0_2061="ROHHADNET syndrome";
var content_f2_0_2061=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F88393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F88393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical manifestations of ROHHADNET syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent of cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <strong>",
"         Hypothalamic endocrine manifestations",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Early and rapid onset obesity",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         100",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Deceleration of growth rate",
"       </td>",
"       <td class=\"centered\">",
"        38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Failed growth hormone stimulation test",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         62",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adrenal insufficiency",
"       </td>",
"       <td class=\"centered\">",
"        29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cushing's syndrome",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypernatremia*",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         62",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diabetes insipidus",
"       </td>",
"       <td class=\"centered\">",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hyperprolactinemia",
"       </td>",
"       <td class=\"centered\">",
"        52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypogonadotropic hypogonadism",
"       </td>",
"       <td class=\"centered\">",
"        43",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Precocious puberty",
"       </td>",
"       <td class=\"centered\">",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Respiratory manifestations",
"        </strong>",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         100",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Cardiorespiratory arrest",
"       </td>",
"       <td class=\"centered\">",
"        57",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Autonomic dysregulation",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Tumors of neural crest origin",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        52",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Adrenal ganglioneuroma",
"       </td>",
"       <td class=\"centered\">",
"        29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Neurobehavioral disorders",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        48",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ROHHADNET: rapid onset obesity, hypothalamic dysfunction, hypoventilation, autonomic dysregulation, and neural crest tumors.",
"     <br/>",
"     * In this case, hypernatremia was defined as consistent blood sodium concentrations of &gt;145 mEq/L (which is &gt;2 SD for age). Paradoxically, some patients have hyponatremia.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Respiratory manifestations typically consist of hypercarbia and hypoxemia during wakefullness, sometimes associated with cyanotic episodes.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Bougneres P, Pantalone L, Linglart A, et al. Endocrine manifestations of the rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation, and neural tumor syndrome in childhood. J Clin Endocrinol Metab 2008; 93 (10):3971-3980.",
"      </li>",
"      <li>",
"       Ize-Ludlow D, Gray JA, Sperling MA, et al. Rapid onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation presenting in childhood. Pediatrics 2007; 120:e179.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_0_2061=[""].join("\n");
var outline_f2_0_2061=null;
var title_f2_0_2062="PEG rHuMGDF after chemotherapy";
var content_f2_0_2062=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    PEG-rHuMGDF stimulates platelet recovery after chemotherapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 312px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients with lung cancer were treated with paclitaxel and carboplatin on day 1 and subsequently with either placebo (blue open circles, n = 12) or various doses of PEG-rHuMGDF (red closed circles, n = 38) and the platelet counts measured daily. The administration of PEG-rHuMGDF was associated with accelerated recovery of the platelet count. Twenty-one days after administration of the chemotherapy, 93 percent of the PEG-rHuMGDF-treated patients but none of those given placebo had recovered to their baseline platelet values (inset).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Fanucchi, M, Glaspy, J, Crawford, J, et al, N Engl J Med 1997; 336:404.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_0_2062=[""].join("\n");
var outline_f2_0_2062=null;
var title_f2_0_2063="Russian forceps";
var content_f2_0_2063=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Russian forceps",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 159px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The unique design of the Russian tissue forceps allows for easy handling of both tissue and surgical needles.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_0_2063=[""].join("\n");
var outline_f2_0_2063=null;
